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Resumo 
 
Haemophilus influenzae é um microrganismo comensal da nasofaringe humana, responsável 
por doenças invasivas e não-invasivas. Este trabalho focou-se no estudo de 93 estirpes de H. 
influenzae, isolados entre 2013 e 2018, de indivíduos com duas doenças não-
invasivas epidemiologicamente relevantes: Doença Pulmonar Obstrutiva Crónica (DPOC) e Otite 
Média (OM). As estirpes foram caraterizadas, fenotípica e molecularmente, relativamente à presença 
de cápsula, produção de β-lactamase, suscetibilidade a antibióticos, diversidade genética por MLST, 
presença/ausência de fatores de virulência (pilA, hifA, hmw1A, hmw2A, hia e ompP5) e a capacidade 
para formar biofilmes.  
A DPOC incidiu numa população adulta (100%), enquanto a OM foi predominante em 
crianças (98,2%). Verificou-se que o H. influenzae não capsulado (HiNC) foi o agente etiológico 
responsável pela DPOC (97,4%) e OM (100%). Relativamente à susceptibilidade aos antibióticos, há a 
destacar a produção de β-lactamase em 15,1% das estirpes. O MLST revelou uma elevada diversidade 
genética, tanto na DPOC como na OM, com a caraterização de 31 STs em 41 estirpes analisadas. Os 
genes pilA e ompP5 foram identificados em mais de 50% dos isolados de DPOC e OM. Os genes hifA 
e hia foram encontrados em menos de metade dos isolados, tendo-se verificado uma maior prevalência 
na OM. Os genes hmw1A e hmw2A foram identificados, respetivamente, em 25,5% e 32,7% das 
estirpes de OM, estando ambos presentes em 76,3% das estirpes de DPOC. A formação de biofilmes 
foi observada em 14,0% e 29,0% das estirpes após 24h e 48h, respetivamente. Não foi possível 
estabelecer uma relação entre formação de biofilmes e origem clínica, nem com a presença de fatores 
de virulência (pilA, hmw1A e hmw2A) envolvidos na produção de biofilmes. 
DPOC e OM são doenças frequentemente associadas a HiNC. Não existindo uma vacina 
disponível, é importante a sua monitorização, pelo impacto social e económico que representam em 
Saúde Pública.  
 
 
 
Palavras-chave: Haemophilus influenzae, DPOC, OM, fatores de virulência, biofilmes, HiNC 
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Abstract 
 
 Haemophilus influenzae is a commensal microorganism of the human nasopharynx, 
responsible for both invasive and non-invasive diseases. This work focused on the study of 93 H. 
influenzae isolates, collected between 2013 and 2018, from patients with two epidemiologically 
relevant non-invasive diseases: Chronic Obstructive Pulmonary Disease (COPD) and Otitis Media 
(OM). Phenotypical and molecular characterizations were performed for the isolates, regarding 
capsular typing, β-lactamase production, antibiotic susceptibility, genetic diversity by MLST, 
presence/absence of virulence factors (pilA, hifA, hmw1A, hmw2A, hia and ompP5) and ability to 
produce biofilms.  
COPD isolates were collected from adults (100%), while 98.2% of OM isolates were collected 
from children. Non-typeable H. influenzae (NTHi) was the aetiological agent in COPD (97.4%) and 
OM (100%). Regarding antibiotic susceptibility, it should be noticed that 15.1% of the isolates were β-
lactamase producers. MLST revealed a high genetic diversity among COPD and OM isolates, with 31 
STs in 41 analysed isolates. pilA and ompP5 genes were present in more than 50% of COPD and OM 
isolates. hifA and hia genes were identified in less than half of the isolates, with a higher prevalence of 
these among OM isolates. hmw1A and hmw2A genes were respectively identified in 25.5% and 32.7% 
of OM isolates, while both hmw genes were present in 76.3% of COPD isolates. Biofilm production 
was observed for 14.0% and 29.0% of all isolates after 24h and 48h, respectively. No relationship 
between biofilm production and clinical source could be established, as well as with the presence of 
virulence factors (pilA, hmw1A e hmw2A) involved in biofilm production. 
COPD and OM are frequently associated with NTHi. Since no vaccines are available, 
monitoring of these diseases is highly recommended, as these constitute a Public Health threat 
associated with a high economic and social burden. 
 
 
 
Keywords: Haemophilus influenzae, COPD, OM, virulence factors, biofilms, NTHi 
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1. Introduction 
 
 
1.1. Haemophilus influenzae 
 
 
 1.1.1. Pasteurellaceae family, Haemophilus genus and Haemophilus influenzae 
 
Pasteurellaceae family belongs to the Pasteurellales order and Gammaproteobacteria class.1 
It is composed of a wide group of gram-negative opportunistic pathogens and commensal organisms, 
which have an important impact on human and animal health.2  
 Currently, the family is composed of 26 genera, including Actinobacillus, Aggregatibacter, 
Avibacterium, Avibacteriumendocarditidis, Basfia, Bibersteinia, Bisgaardia, Chelonobacter, 
Cricetibacter, Frederiksenia, Gallibacterium, Haemophilus, Histophilus, Lonepinella, Mannheimia, 
Mesocricetibacter, Muribacter, Necropsobacter, Nicoletella, Otariodibacter, Pasteurella, 
Phoconobacter, Testudinibacter, Ursidibacter, Vespertiliibacterpulmonis, and Volucribacter.3  
Haemophilus, Actinobacillus and Pasteurella are considered the three main classic genera.2  
 Of the Haemophilus genus, four species possess host specificity for animals (H. parasuis, H. 
felis, H. paracuniculus and H. haemoglobinophilus) and nine for humans (H. influenzae, H. aegyptius, 
H. haemolyticus, H. parainfluenzae, H. ducreyi, H. pittmaniae, H. sputorum, H. paraphrohaemolyticus 
and H. parahaemolyticus).2  
 
H. influenzae was first described by physician Richard Pfeiffer in 1892. The bacilli were 
detected during the epidemic of the influenza virus, in sputum samples of patients suffering from this 
infection and was then named as “The influenza Bacillus”.4 In 1931, Margaret Pittman detected two 
different types of colonies grown on agar plates.5 These two types differentiated in size and 
opaqueness. One type of colonies was described as large, smooth, mucoid, slightly opaque and 
iridescent when observed in obliquely transmitted light and were denominated as S (Smooth) isolates; 
the second type of colonies were smaller, translucent, non-iridescent with transmitted light, with a 
rough surface, being denominated as R (Rough) isolates. S isolates appeared to be more virulent for 
laboratory animals and, in all of them, it was detected the presence of a capsule. This finding led to a 
differentiation of H. influenzae into isolates with a capsule, or typeable, and isolates lacking a capsule, 
also referred to as Nontypeable isolates (NTHi) (Fig. 1.1).  
H. influenzae are small gram-negative, coccobacilli, pleomorphic and fastidious bacteria. This 
bacterium grows optimally with temperature between 35 and 37 ºC, in an atmosphere supplemented 
with 5–10 % of CO2. Regarding in vitro growth, it is dependent on X-factor and V-factor – also known 
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as haemin and Nicotinamide Adenine Dinucleotide (NAD), respectively.6 The X-factor consists of a 
Ferric Ion (Fe3+) inserted in the centre of a porphyrin ring (protoporphyrin IX), with Chloride Ion (Cl-) 
as a ligand.7 It can be used, optionally, for anaerobic growth. The V-factor is a pyridine nucleotide that 
possesses important roles in metabolic conversions, such as signal transducers, plays a major role as 
electron carrier in oxidoreductase reactions and is essential for growth.8,9  
H. influenzae is an important human-restricted commensal of the nasopharynx. A longitudinal 
study conducted in Portugal by Sá-Leão and colleagues10 collected 414 nasopharyngeal samples of 
children from a day care center, during one year. The authors stated that H. influenzae was present in 
87% of the nasopharyngeal samples. In addition, all children were colonized with this bacterium, at 
some point of the study and 34% were persistently colonised, highlighting the importance of this 
bacterium as a colonizer of the respiratory tract.  
 
 
 
Similar to all gram-negative microorganisms, the cell wall of H. influenzae is composed of a 
layer of peptidoglycan – cross-linked by Penicillin-Binding Proteins (PBPs) – that confers strength, 
resistance against antibiotics and protects bacteria against lysis due to variations in osmotic pressure. 
Outer and inner membranes also protect bacteria against antibiotics, by hampering them from reaching 
the cytoplasm, where these could interfere with protein synthesis. These membranes serve as barriers 
of outer, as well as inner permeability.11 Lipooligosaccharides (LOS) are endotoxins present on the 
bacterial cell wall and are fundamental for bacterial adhesion.12 Although H. influenzae lacks flagella, 
Figure 1.1 | (A) NTHi colonies and (B) encapsulated H. influenzae colonies in chocolate agar plates 
supplemented with polivitex. Both photographs were taken during this Master’s Thesis, with an Otitis Media 
isolate included in the study (A) and an invasive serotype e isolate belonging to the collection of the reference 
laboratory (B). 
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NTHi isolates commonly possess pili structures, which have been associated with twitching motility 
(non-flagellar based type IV pilin-dependent motility).13 
 
 
1.1.2. Haemophilus influenzae serotypes 
 
H. influenzae can be classified as encapsulated, or non-encapsulated based on the production 
of a capsular polysaccharide. 
 Encapsulated H. influenzae isolates are divided into six distinct serotypes, a, b, c, d, e, f – also 
referred to as Hia, Hib, Hic, Hid, Hie and Hif – based on the production of different capsular 
polysaccharides. Capsular polysaccharides confer virulence by avoiding complement system lysis.14 
H. influenzae capsular serotypes may be organised into three groups, each composed of two serotypes, 
based on both the structures of the polysaccharides and an association with their resistance to 
antibody-free complement lysis effect.14 Types b and a were considered the most virulent, being 
composed of a phosphodiester, a neutral sugar and an alcohol (ribitol). Types c, d, e and f were much 
less virulent, with types c and f being considered of intermediate complement resistance and 
composed of a phosphodiester, a N-acetylated amino sugar and a monosaccharide. Finally, types d and 
e possessed the least resistance to complement action and have a repeat unit of a N-
acetylmannosamine uronic acid and N-acetylglucosamine.14 Encapsulated isolates are thus more 
virulent and tend to be associated with invasive disease, such as septicaemia and meningitis.6  
 Although NTHi isolates lack a polysaccharide capsule, they can be differentiated by Outer 
Membrane Proteins (OMPs), LOS and High Molecular Weight (HMW) protein profiles, among other 
virulence factors, such as Hif and Hap adhesins, for instance.15 NTHi isolates are usually associated 
with non-invasive diseases, of the upper (e.g.: Otitis Media [OM] and sinusitis) and lower respiratory 
tract (e.g.: chronic obstructive pulmonary disease [COPD] and cystic fibrosis).16  
 
 
 1.1.3. Molecular typing 
  
  1.1.3.1. Capsular typing 
 
 Capsular typing by molecular methods is considered the most accurate technique to 
differentiate NTHi from encapsulated isolates and for identification of H. influenzae serotypes.17  The 
region of the chromosome of H. influenzae responsible for capsule expression is named the “cap 
locus”, which is described in all six capsular serotypes. It is composed of three different regions: 1, 2 
and 3.18 Regions 1 and 3 are common to all serotypes and are composed of a highly conserved cluster 
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of genes, essential for processing and exporting capsular material to the cell surface. These two 
regions flank a serotype-specific region, region 2, which appears to be unique to each capsular 
serotype and contains genes involved in the synthesis and polymerization of the capsular 
polysaccharide (Fig. 1.2).18,19  
 
 
Figure 1.2 | Schematic presentation of the cap b locus. bex genes are located in region 1 of the cap locus, 
downstream from insertion element IS1016. Region 2 possesses capsule-specific genes and region 3 is 
responsible for post polymerization. (adapted from19) 
 
 
 Most Hib isolates usually possess a partial duplication of a DNA fragment. This 
duplication includes two copies of regions 2 and 3, one copy of region 1 and a truncated copy of 
region 1 with a deletion between the insertion element IS1016 and bexA sequences.19  However, these 
isolates may undergo a recombination event that leads to the loss of the complete copy. The truncated 
copy would remain, with a loss of part of the coding sequence located downstream of the start of 
functional bexA gene, which is essential for the exportation of the capsular polysaccharide to the cell 
surface. This results in a capsule-deficient mutant, referred to as b- mutant, or Hib-minus.19 Falla and 
colleagues have developed a Polymerase Chain Reaction (PCR) capsular serotyping method that has 
been used as a standard protocol for typing H. influenzae.20 This method distinguishes NTHi isolates 
from encapsulated ones, by amplification of bexA gene, which is exclusively present in encapsulated 
isolates. The authors were able to obtain an amplification product of 343 base-pairs (bp), confirming 
the presence of this gene in encapsulated isolates. In addition, the authors further designed type-
specific primers to all six capsular serotypes enabling a differentiation of each capsular serotype.
  
 
  1.1.3.2 Multilocus Sequence Typing 
 
  H. influenzae genetic diversity studies have been conducted since the 1980’s. Musser 
and colleagues21 showed that encapsulated isolates tended to be phylogenetically related in a limited 
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number of clusters according to each serotype, which suggested that isolates belonging to a certain 
serotype show limited genetic diversity. The authors hypothesised that since H. influenzae is a 
naturally competent microorganism, the capsule may serve as a barrier for the uptake of extracellular 
DNA, which probably contributes to the clonal structure of encapsulated isolates. In fact, genetic 
diversity in NTHi isolates is mostly due to horizontal genetic exchange.12  
  NTHi isolates have been shown to be electrophoretically distant from serotype b and 
even Hib-minus isolates, presenting a very heterogeneous population, unlike encapsulated population. 
Considering NTHi heterogeneous population structure, Chiara and colleagues15 were able to organize 
NTHi population into six different clades (I-VI) according to the presence/absence of six virulence 
factors, supporting a capacity of clonal evolution in the NTHi population.  
  Initial studies were mostly conducted by Multilocus Enzyme Electrophoresis (MLEE), 
with a main focus on the electrophoretic mobility patterns of major OMPs. However, despite of the 
elucidations provided by MLEE regarding the clonal structure of the encapsulated population and 
great diversity of NTHi isolates, an alternative method – Multilocus Sequence Typing (MLST) – was 
developed as a standard for studies of genetic diversity in H. influenzae species. 
  MLST aimed to address two major issues related to epidemiological surveillance: first, 
to understand if the isolates collected from a certain outbreak were equal, or different from the one that 
started the outbreak. Second, to know if a possible correlation between isolates causing a disease in a 
specific geographic area and worldwide collected isolates could be established.22 Therefore, a focus 
was turned into identifying alleles in the nucleotide sequences of housekeeping genes. Considering 
that MLST provided analysis of nucleotide sequences instead of enzymatic electrophoretic patterns, it 
enabled the identification of more genetic variations, than MLEE. Furthermore, this technique 
permitted comparisons of sequences data between laboratories, due to the existence of worldwide 
databases.23 MLST analyses internal fragments of 450–500 bp from seven selected housekeeping 
genes. Each gene has its sequence assigned to an allele number and the alleles at the seven loci 
provide an allelic profile, which in turn defines the Sequence Type (ST) for each isolate. Since the 
accumulation of nucleotidic changes in housekeeping genes is considered a slow process, the allelic 
profile of a certain bacterial isolate is stable enough in time, allowing this method to be regarded as 
ideal for epidemiologic studies.22 The STs are then displayed in a dendrogram that enables to establish 
a correlation between identical, or highly similar, allelic profiles of isolates. Thus, a phylogenetic 
relation may be inferred.24  
  In the specific case of H. influenzae, Meats and colleagues23 selected Adenylate 
Kinase (adK), ATP Synthase F1 Subunit Gamma (atpG), Fumarate Reductase Iron-Sulfur protein 
(frdB), Fuculokinase (fucK), Malate Dehydrogenase (mdh), Glucose-6-Phosphate Isomerise (pgi) and 
RecA protein (recA) genes that were separated in the genome by a minimum of 120 kb, with the 
exception of recA and fucK (only separated by 22 kb). The sequences for each allele are uploaded to 
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Haemophilus influenzae MLST Database (https://pubmlst.org/hinfluenzae/), where a number is 
assigned to each allele and an ST to each isolate profile.23  
   
 
 
1.2. Haemophilus influenzae infections 
 
H. influenzae is a human-restricted commensal microorganism found in the nasopharynx of 
the respiratory tract, which makes it an ongoing source of potential infections in the upper and lower 
respiratory tract, as it is the case of OM, COPD, pneumonia, cystic fibrosis and bronchitis, in addition 
to invasive diseases.25 
 
 
1.2.1. Invasive disease 
 
In 2018, the European Commission26 updated the definition of invasive disease caused by H. 
influenzae as the isolation of this bacterium, or its nucleic acids from a clinical sample of a biological 
fluid considered sterile, such as blood, or cerebrospinal fluid, for instance. In Europe, the Surveillance 
Report of the European Centre for Disease Prevention and Control (ECDC) showed that the 
distribution of invasive H. influenzae disease tends to follow a seasonal pattern and the highest number 
of reported cases seems to occur during winter months, with a great decrease in August. From this 
month on, the number of cases increases until the end of the year.25,27  
 
 
 1.2.2. Non-invasive disease 
 
  1.2.2.1. Chronic Obstructive Pulmonary Disease  
   
  World Health Organization (WHO) has defined COPD as a disease that can be 
characterized by an airflow limitation, which is usually progressive and associated with alveolar or 
airway abnormalities of the lungs to certain noxious gases and particles. Patients with this disease 
usually present a chronic inflammation of the airways and parenchymal destruction.28 Inflammation, 
pathological changes in the peripheral airways and lesions of the lungs are known to be induced by 
cigarette smoke, in addition to inhaled toxicants and possible occupational exposures to dust and 
smoke.28,29 Chronic inflammation of bronchi and bronchioles leads to the development of emphysema 
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and alteration of the airways and vasculature. Airway obstruction and tissue destruction ultimately 
reduce the capacity of lungs for gas exchange.30 
  COPD is currently the fourth leading cause of worldwide death and it is estimated to 
rank as third in 2020.28 According to WHO, there was a prevalence of 251 million worldwide cases of 
COPD in 2016 and 3.17 million deaths were caused by this disease in 2015.31 Additionally, this 
organization stated that despite of COPD being previously more common in men than women, due to 
increased tobacco smoking among women (in high-income countries) and a higher risk of exposure to 
indoor pollution (in low-income countries), this disease now equally affects both genders.32 
  Exacerbations are changes in the baseline dyspnea, sputum and/or cough of the patient 
that goes beyond the usual variability.33 Interestingly, it is estimated that approximately 50% of all 
COPD exacerbations are actually caused by bacterial infections, being NTHi, along with 
Streptococcus pneumoniae and Moraxella catarrhalis, the most frequent aetiological agents.34,35 NTHi 
may be present in both stable and exacerbated states and it has been shown that patients colonised with 
this bacterium in the stable state tend to present more symptoms and sputum purulence during an 
exacerbation than non-colonised patients. Additionally, these patients present more cough, may take a 
longer period of time to recover from a peak flow at an exacerbation and present a higher exacerbation 
frequency.36 Furthermore, a patient can be colonised by more than one isolate of NTHi and acquisition 
of a new isolate is related to occurrence of an exacerbation. Sethi and colleagues37  have demonstrated 
that, in the majority of cases, after an exacerbation related to NTHi, serum antibodies are produced 
specifically to target that newly acquired isolate. However, this immunological response is only 
efficient against homologous isolates, and has no effect in newly acquired heterologous isolates. The 
authors postulate that these results may elucidate a mechanism that explains recurrent exacerbations, 
in COPD patients, in the presence of H. influenzae.  
  Given the significant role of bacteria in exacerbations, most of the patients are treated 
with antibiotics. However, since clinical features do not distinguish between bacterial and non-
bacterial exacerbations, the benefits of the treatment would not be as successful in non-bacterial 
exacerbations.38 In Portugal, empirical treatment recommended is amoxicillin, with or without 
clavulanic acid, macrolides, or doxycycline. However, it is recommended that antibiotics against 
COPD should only be taken by a patient previously confirmed to have bacterial exacerbations and not 
by a patient in a stable-state.39 
 
  1.2.2.2. Otitis Media  
   
  Otitis Media (OM) are inflammatory and infectious conditions that affect the middle 
ear. Infection occurs when bacteria migrate, through the Eustachian tube, from the nasopharynx to the 
middle ear, which is an event usually triggered by a viral infection.40  
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   OM may be manifested either by acute, or chronic episodes. Three of its most 
common conditions are Acute Otitis Media (AOM), Otitis Media with Effusion (OME) and Chronic 
Suppurative Otitis Media (CSOM). AOM may be caused by either viruses or bacteria and common 
symptoms include otalgia and fever.41 OME, on the other hand,  is a chronic inflammation.41 Common 
symptoms are glue ear fluid (presence of fluid in the middle ear space behind the eardrum) with 
absence of acute signs, and hearing loss is a possible consequence.42 CSOM is a chronic inflammation 
characterized by suppurative middle ear infection established for a long period of time and with 
perforation in the tympanic membrane, in most of the cases.41   
  In 2012, Monasta and colleagues43 conducted a review with data from 1980 to 2008 
with relevant worldwide information regarding AOM and CSOM. From the information they gathered, 
the authors observed that the global AOM incidence rate is estimated as 709 million cases per year, 
with 51% of the cases being registered in children under the age of five. In Central Europe, 40% of the 
cases occurred in children with ages ranging from less than one to five years old. CSOM, on the other 
hand, registered 31 million cases each year, with 22.6% of these cases occurring in children under the 
age of five years old. As for mortality rates, the authors estimated that approximately 21,000 people 
die, each year, due to complications related with OM. The authors stated that, although the mortality 
rates associated with OM are relatively low, when considering the overall combination of AOM and 
CSOM, plus respective sequels, the numbers should be considered relevant, more specifically in the 
first five years of life.43  
 The most common treatment against AOM, in Portugal, is antibiotic administration. 
Amoxicillin, or amoxicillin-clavulanate are the elected choices for treatment of OM infections. 
Second, or third, generation cephalosporins may be an alternative in the case of ineffectiveness of the 
first-line antibiotic, or for penicillin allergic children.44 
  A 10-valent pneumococcal nontypeable Haemophilus influenzae protein-D conjugate 
vaccine – PHiD-CV (SynflorixTM) – was developed against H. influenzae and 10 serotypes of S. 
pneumoniae.45 Using protein D as carrier relates to it being a surface protein mostly conserved in both 
encapsulated and NTHi isolates, serving as antigen.45,46 Thus, this vaccine contains 8 serotypes of S. 
pneumoniae  individually conjugated to a non-lipidated recombinant form of protein D, one serotype 
conjugated with tetanus toxoid and the remaining with diphetheria toxoid. A protective effect of 
protein D as carrier was demonstrated in a predecessor study of an 11-valent vaccine that showed a 
reduction of 57.6% and 35.3% of AOM episodes caused by S. pneumoniae and NTHi, respectively. 
The effectiveness of the 10-valent vaccine was then expected to be similar to that of the 11-valent 
vaccine.45,46 
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1.3. Epidemiology 
 
 Due to the severity of invasive diseases, most epidemiologic studies available in literature are 
focused on these. Limited information is available regarding non-invasive diseases caused by H. 
influenzae. Therefore, the surveillance data here presented are related to invasive disease reports.   
Conjugated Hib vaccine induces bactericidal antibodies to respond against Polyribosylribitol 
Phosphate (PRP), a capsular polysaccharide, regarded as a major virulence factor.47  
In the pre-vaccine era, serotype b was one of the major causes of meningitis in children, 
particularly under five years old.48 In the United Kingdom (UK), a survey conducted in this period49 
revealed that from all H. influenzae reported cases, 82% were caused by Hib, 88% were registered in 
children under five years old, and meningitis was the most common infection. In the United States of 
America (USA), 3–6% of infected children would die and in 20–30% of survivors, permanent mental 
retardation, or mild hearing loss were common sequels.47  
Hib vaccines were first available in the European Union and European Economic Area 
(EU/EEA) in 1989.48 WHO reported that Hib vaccine is currently used as part of the routine 
immunization programme in 192 countries,50 including all EU/EEA member states.25  
In the post-vaccine era, although a decrease of infections caused by Hib was observed, 
invasive disease caused by NTHi increased. Among encapsulated isolates, a major incidence has been 
reported for serotype f, in Europe.25  
An epidemiologic study comprising the years of 2007 and 2014 in 12 European countries51 
showed that, overall, 78% of invasive cases were caused by NTHi and low notification rates for Hib 
supported the efficacy of Hib vaccine. The authors highlighted that these trends may be a result of 
improved surveillance programs, physicians awareness and even better serotyping techniques that 
were not available in the pre-vaccine era. 
In 2015, ECDC reported 3,162 cases of invasive disease, caused by H. influenzae, confirmed 
in 30 European countries (Fig.1.3). Invasive cases were reported, mostly in children under the age of 
one and in elderly people over 65 years old.25 It was further reported that 82% of all cases were caused 
by NTHi and that these were the most common cause of infection in all ages. Regarding encapsulated 
isolates, Hif, Hib and Hie accounted for 9%, 4% and 3% of all cases, respectively and the remaining 
cases were caused by Hia, Hic and Hid. Hie and Hif serotypes seemed to mostly affect people over 45 
years of age. 
Despite of worldwide surveillance data, comparisons of H. influenzae disease incidence 
between countries and overtime trends of infection should be carefully evaluated, since these are 
dependent on policies and surveillance systems of each country, along with reporting processes and 
case detection methods.48  
Since Hib vaccines specifically target the polysaccharide capsule of serotype b, these are 
ineffective against NTHi isolates and even against the remaining encapsulated serotypes. Several 
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studies testing protein-D and protein-E have been conducted, but the development of an effective 
vaccine against NTHi is still an ongoing subject of research.52,53  
 
 
In Portugal, epidemiological data covers three distinct periods: 1989–2001,54 2002–201055 and 
2010–2014,56 with the last period being specific to paediatric cases. All these studies were related to 
H. influenzae invasive disease and the results were in agreement with studies described above.25,51  
Hib vaccine was available in Portugal, in 1994, being then recommended for children under 
five years old. It was implemented as part of the National Vaccination Programme in the year 2000. 
The first study period, 1989–2001, includes the pre-vaccine era. During this period, a majority of Hib 
isolates was characterized (60.5%) followed by NTHi (38.6%) and the first case of a Hif isolate was 
reported. Along with a decrease in the number of Hib infections, a decrease in multidrug resistance 
was also reported, which may be explained due to most of the resistant isolates being, then, of serotype 
b.54  
Between the years 2002 and 201055 prevalence of Hib invasive disease was much lower 
(13.2%), NTHi isolates accounted for the majority of cases (77.1%) and non-b serotypes appeared to 
be emerging, with reports of serotypes a (2.1%) and f (6.9%). Serotype d is a rare serotype that was 
characterized in Portugal for the first time in 2009 and since then, no other serotype d isolate was 
found among Portuguese disease.57 
Figure 1.3 | Distribution of invasive H. influenzae disease cases per 100,000 population, in each EU/EEA 
country, in 2015. (adapted from25) 
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The paediatric study in the period 2010–201456 reported NTHi isolates as being responsible 
for the majority of the cases (65.7%). Hib was characterized in nine children (23.7%), six of which 
were considered vaccine failures.  
 
 
 
1.4. Antibiotics in Haemophilus influenzae 
 
 Antibiotics are biological, or synthetical, substances that either possess the ability to inhibit 
bacterial growth, or kill bacteria, which characterizes them as bacteriostatic, or bactericidal, 
respectively.58 Nowadays, it is recognized that infectious diseases are still a leading cause of 
worldwide death and antimicrobial resistance is a topic of great concern. Antibiotics with a similar 
structure present identical patterns of toxicity, effectiveness and potential side effects.58  
β-lactams usually possess a highly reactive ring – as a common structure – and include 
penicillins (e.g.: ampicillin, amoxicillin), cephalosporins (e.g.: cefepime, cefotaxime, cefuroxime) and 
carbapenems (e.g.: meropenem).58  
These antibiotics usually target PBPs, which are fundamental for synthesis of the bacterial cell 
wall, as they cross link peptide units in peptidoglycan production. Covalent bonding with antibiotic 
disrupts the process by weakening peptidoglycan and the cell eventually bursts, due to osmotic 
pressure.58-60 
 Macrolides (e.g.: azithromycin) and tetracyclines bind to bacterial 50S and 30S ribosome 
subunit, respectively, which stops addition of amino-acids to polypeptide chains, ultimately resulting 
in inhibition of protein synthesis. Quinolones (e.g.: ciprofloxacin) interfere with DNA replication, by 
inhibiting the action of DNA gyrase, an enzyme that introduces negative supercoils in DNA during 
replication. Other agents, such as chloramphenicol, rifampicin and trimethoprim-sulfamethoxazole, 
may act as inhibitors of the 50S ribosome subunit, DNA replication and folic acid metabolism, 
respectively.58,59,61  
 For treatment of H. influenzae infections, β-lactams are commonly used, since the outer 
bacterial membrane presents little resistance to penetration of this class of antibiotics.60 However, 
resistance mechanisms against them have been reported and thoroughly studied over the last decades. 
The most common bacterial resistance mechanisms include efflux pumps, modification of the 
target molecule and inactivation of the antibiotic through enzymatic action.59  
 
 
Haemophilus influenzae in Chronic Obstructive Pulmonary Disease and Otitis Media 
12 
 
1.4.1. β-lactams resistance mechanisms in H. influenzae 
 
In H. influenzae, both enzymatic and non-enzymatic mechanisms have been reported and 
production of β-lactamase constitutes the most common resistance mechanism against β-lactams.62  
 
1.4.1.1. β-Lactamase-Positive Ampicillin-Resistant (BLPAR) isolates 
 
  In 1972, the first report of ampicillin resistance in H. influenzae was registered and 
was related to the production of TEM-1 β-lactamase, which is encoded by blaTEM-1 gene. H. influenzae 
rarely produces a second β-lactamase, ROB-1, encoded by the blaROB gene.62  β-lactamases hydrolyse 
the ester-amide bond in β-lactams, which interferes with the structure of the antibiotic and, ultimately, 
its effectiveness (Fig. 1.4).59,63 
 
 
 
 
 
 
 
 
 β-lactamases may be divided into four classes, from A to D, according to similarities 
in their structure. Classes A, C and D possess a serine residue in the active site, whereas class B are 
metalloproteins that require zinc as a cofactor.64 TEM-1 and ROB-1 are class A β-lactamases.62 
  As a solution for β-lactamase producing H. influenzae isolates, alternative treatments 
that combine amoxicillin and clavulanic acid have been administered to patients.65,66 In the presence of 
clavulanic acid, β-lactamase irreversibly binds to its β-lactam ring, which inactivates the enzyme and 
prevents it from binding to β-lactams.67 
 
1.4.1.2. β-Lactamase-Negative Ampicillin-Resistant (BLNAR) isolates 
  
 Ampicillin-resistant isolates that do not produce β-lactamase have been reported and 
designated as BLNAR. Usually, these isolates possess altered PBPs with reduced affinity for β-
lactams, due to amino-acid substitutions in this protein.68 In addition to ampicillin, BLNAR isolates 
also present reduced susceptibility for other β-lactams, such as cephalosporins.62 In opposite to β-
Figure 1.4 | Penicillin inactivation through β-lactamase production. (adapted from63) 
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lactamase producing isolates, clavulanic acid has no effect in BLNAR isolates, due to lack of the 
target enzyme.69  
 H. influenzae possesses eight PBPs, PBP1 – PBP8.62 Mutations in ftsI gene, which 
encodes PBP3, have been reported and are useful to confirm phenotypically identified BLNAR 
isolates. More specifically, amino-acid substitutions close to conserved KTG (K512TG) and SSN 
(S379SN) motifs in the transpeptidase domain of PBP3 are believed to be mostly responsible for 
antibiotic resistance.68 However, there is still not a clear definition for BLNAR isolates, since some 
authors define them based on ampicillin-resistance breakpoint, while others consider ampicillin-
intermediate isolates.62  These isolates can only be accurately identified by sequencing the ftsI gene.68 
 
  1.4.1.3. β-Lactamase-Positive Amoxicillin-Clavulanate-Resistant (BLPACR) isolates 
  
 BLPACR isolates possess both the production of β-lactamase and modified PBPs, 
which means that these are resistant to β-lactams, such as ampicillin and amoxicillin-clavulanate as 
well. Most authors define these isolates considering the amoxicillin-clavulanate breakpoint, but 
mutations identified in the ftsI gene ultimately serve as confirmation.62,69,68 BLPACR isolates have 
higher amoxicillin resistance levels than BLNAR isolates, due to the presence of β-lactamases.69  
 
 
 
1.5. Virulence factors 
 
 Identifying and understanding how virulence factors influence pathogenic, or commensal 
behaviour is very important and this is, nowadays, a main focus in NTHi research.12 H. influenzae has 
developed several mechanisms to resist immune responses and to adhere, persist and, consequently, 
invade host cells.70,71   
 
 
 1.5.1. Adhesion 
  
The very first step in the NTHi pathogenesis is adherence of bacteria to the mucosa, after 
initial interaction.70,71    
To avoid complement system immune responses, encapsulated isolates usually rely on the 
presence of a capsule for protection against deposition and/or binding of host complement factors, or 
immunoglobulins. NTHi isolates, however, have to develop alternative defence mechanisms against 
host immune responses.70 One of the most important is inactivation of Immunoglobulin A (IgA) which 
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is the most common immunoglobulin in nasal secretions. Both Hib and NTHi isolates may produce 
IgA protease, which cleaves IgA1 antibodies into Fc and Fab fragments.72  
LOS are lipopolysaccharides, with shorter saccharide chains, considered to be essential for 
interaction of bacteria with host cells.12 These structures vary among bacterial cells of the same isolate 
and also between different isolates, which naturally affects interaction and invasion of host cells. LOS 
are present in both Hib and NTHi isolates.71  
 For adherence to host mucosa, H. influenzae also counts on the expression of several adhesins, 
which are proteins that facilitate this action.73 Five important adhesins, HifA, HMW1, HMW2, 
Hia/Hsf and Hap, have been identified in encapsulated (Hib) and NTHi isolates.71 Piliated adhesins 
include PilA and HifA proteins. PilA was shown to be essential for NTHi adherence to epithelium and 
twitching motility, since experiments with pilA-mutant isolates demonstrate a significant reduced 
ability of isolates to properly accomplish these mechanisms.13 Kubiet and colleagues74 have also 
shown that for both Hib and NTHi isolates, absence of HifA pili significantly decreases the ability of 
isolates to adhere to mucin and that pre-treatment with antibodies that specifically targeted HifA has a 
similar effect.   
However, isolates that lack pili structures still have the ability to adhere to human epithelium, 
which suggests expression of non-piliated adhesins. For instance, non-piliated high molecular weight 
proteins, HMW1 and HMW2, are present in encapsulated non-type b and most NTHi isolates, in 
addition to Hia protein, which seems to be a substitute for HMW-deficient isolates.75-77  
 
  1.5.1.1. pilA 
   
  pilA is a highly conserved gene that is present in, approximately, 100% of NTHi 
isolates,13,78 (Table 1.1).  This gene is one of the four-member gene cluster pilABCD, expressing Type 
IV Pilin (Tfp). Bakaletz and colleagues13 have showed that expression of pilA is essential for pilus 
structures on the bacterial surface. pilA expression has been shown to be necessary for proper 
adherence, biofilm formation and epithelium colonization. Jurcisek and colleagues79 demonstrated that 
pilA mutants showed diminished capacity for in vitro adherence, which translated into loss of ability to 
colonize in vivo and decreased stability of biofilms in chinchilla middle ear. Tfp structures additionally 
play a significant role in competence, as these help the uptake of extracellular DNA through bacterial 
membranes.80 Pili structures have also been suggested to mediate interbacterial interaction, since pilA-
mutants present thinner and biomass decreased biofilms.80  
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  1.5.1.2. hifA 
   
  HifA, encoded by hifA gene, is a structural subunit of the pilus structure encoded by 
hifABCDE cluster. This protein mediates adherence to eukaryotic cells, by specifically binding to 
sialyl-lactosylceramide ganglioside receptor on epithelial cells. Expression of hifA is essential for 
adherence, since inactivation of this gene highly hampers the ability of H. influenzae to adhere to 
epithelial cells.81 Analysis of amino-acid sequences revealed conserved and variable regions, in which 
variable regions possibly result in different antigenic sites.82 Geluk and colleagues82 found that 
hifABCDE cluster is present in both Hib and NTHi isolates with 18% of NTHi isolates possessing 
hifABCDE cluster (Table 1.1). The authors additionally suggested that H. influenzae probably loses the 
ability to express fimbriae structures inside tissues, as a defence mechanism to avoid clearance. 
Although HifA plays a role in adherence to mucosa, other factors such as HMW proteins are also 
important for establishment of binding to epithelium.74,82  
 
  1.5.1.3. hmw1A and hmw2A 
   
  hmw1A and hmw2A genes encode HMW1 and HMW2 proteins, respectively. These 
genes present 80% similarity and are 71% identical.83 Despite of highly similar, HMW1 and HMW2 
proteins possess different binding specificities: while HMW1 is specific for sialylated glycoprotein 
receptor containing sialic acid, a recent study has shown a high affinity of HMW2 to 2-6 linked N-
acetylneuraminic acid, suggesting that this may be the receptor.84 Both proteins mediate attachment to 
Chang epithelial cells.76,85 van Schilfgaarde and colleagues86 conducted a study for comparison of 
adherence, hmw presence/absence and expression of HMW proteins in NTHi isolates. The authors 
found that isolates presenting both hmw genes and HMW proteins represented 72% of all isolates 
capable of adherence. These results highlighted a correlation between HMW and capacity for 
adherence. Other studies also corroborate the importance of expression of hmw genes for 
adherence.76,78 A study conducted by Ecevit and colleagues87 found, in NTHi isolates, percentages of 
51% and 23% for hmw1A and hmw2A, respectively, while others have found prevalence for both 
genes from 55 to 100% of isolates (Table 1.1).78,88  NTHi isolates that do not express HMW proteins 
are still able to adhere, since other adhesins, such as Hia and OMP P5, may serve as alternative 
adherence mechanisms.78  
 
  1.5.1.4. hia 
   
  Hia adhesin is encoded by hia gene and has been described for 32% to 55.6% of NTHi 
isolates (Table 1.1).87,89 Hia seems to act as a substitute for HMW1/HMW2 with adherence function 
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when these are absent, since hmw and hia genes are mutually excluded in both NTHi and non-type b 
encapsulated isolates.75,77 In fact, hia has been described to be present in over 80% of NTHi isolates 
lacking both HMW1 and HMW2 proteins.90 However, a receptor for Hia still remains unidentified.91 
In the chromosome, hia and hsf are located in the same region. Although these genes encode proteins 
with similar functions, hia is present in NTHi isolates, while hsf is the major non-pilus adhesin of Hib 
isolates. Non-type b encapsulated isolates also possess a gene homologous to hsf.75  
 
1.5.1.5. ompP5 
   
  OMP P5 is a β-barrel outer membrane protein. It is encoded by ompP5 gene and is a 
member of the OmpA protein family,92,93 which has been identified from 52% to 100% of NTHi 
isolates (Table 1.1).78,92 OMP P5 binds to mucin and surface-expressed Carcinoembryonic Antigen-
Related Cell Adhesion Molecule-1 (CEACAM1) receptor.93 Duim and colleagues analysed NTHi 
isolates from patients with chronic bronchitis and verified that, regarding ompP5, all isolates had 
conserved sequences, in addition to diverse regions located on the cell surface. These diverse regions 
resulted in OMPs with different molecular weights. The authors explain that this diversity may have 
resulted from selective pressure, which becomes an advantage of these isolates in persistence during a 
chronic infection.94 Similar results have been found by other authors when analysing isolates from 
patients with non-respiratory and respiratory diseases, as well as with exacerbations of chronic 
diseases (COPD isolates included).92 Vuong and colleagues described that 13% of isolates lacking 
hmw1A and hmw2A genes, had ompP5 gene and these were still capable of adherence. The authors 
stated that although these results were not statistically significant, these may elucidate the importance 
of OMP P5 in adherence.78  
 
 
1.5.2. Persistence and invasion 
  
 Ability of H. influenzae to adhere and persist on the mucosa is especially favoured in patients 
with underlying diseases of the upper and lower respiratory tract, in which mucociliary clearance is 
hampered.74 After adherence has been established, persistence on the mucosa is the following step. In 
order to persist, H. influenzae depends upon a constant supply of iron and heme, among additional 
nutrients from the surrounding environment. Uptake of nutrients not only promotes survival, but also 
bacterial replication. Furthermore, bacteria must develop further mechanisms to resist host immune 
system responses.70,71  
Most of iron in mammalian hosts is kept as heme components, inside ferritins, or bound to 
transferrins, meaning that its availability is much limited for invading microorganisms. Hib and NTHi 
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isolates count on Transferrin-Binding Proteins (Tbp), Tbp1 and Tbp2, for direct iron uptake from 
transferrins.95 For heme uptake, H. influenzae uses hemoglobulin and Hemoglobulin:Haptoglobolin 
binding Proteins (Hgp), encoded by hgp genes and Heme-Hemopexin (HxuC), the most important 
complexes for heme binding and transfer to cytoplasm.96 
 
 
Table 1.1 | Distribution of virulence genes among NTHi isolates. 
Gene Prevalence Reference 
pilA ~ 100 % Bakaletz et al., 200513  and Vuong et al., 201378 
hifA 
 
 
~ 18 % 
 
 
 
Geluk et al., 199882 
 
hmw 1A 51% 
55–100 % 
Ecevit et al., 200487 Vuong et al., 2013, 78 and Busher 
et al., 200488 hmw 2A 23% Ecevit et al., 200487 
   
 
hia 
 
 
32% ; 55.6% 
 
 
 
Ecevit et al., 200487 and Cardines et al., 200789 
 
 
ompP5 
 
52% ; 100 % 
 
Vuong et al., 201378 and Martí-Lliteras et al., 201192 
  
  
In addition to genetic diversity, H. influenzae has the ability to express phase variable 
virulence factors. Phase variation is an adaptation mechanism developed when bacteria are faced with 
changes in the surrounding environment, or must resist certain immune responses. It involves a 
variation of a structure and is usually associated with the number of nucleotides in a gene sequence.71 
This means that each isolate may independently express some genes and switch-off different ones, 
considering the surrounding environment. The result is hundreds of different H. influenzae virulence 
phenotypes in a single culture, which can be translated to different structures of LOS, or expression of 
fimbriae surface antigens. Ultimately, the phenotype that better fits the environment requirements is 
the one that persists. Therefore, there is a very high probability that phenotypes of the same isolate 
observed in vivo and in vitro may quite differ.12,91 Key targets of phase variation are structures 
important for virulence behaviour, such as HMW1 and HMW2 proteins, or OMP P5. Loss of fimbria 
structures, once inside tissues, may also be helpful for avoidance of clearance.73,82,94  
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 Hap protein was shown to be a major virulence factor for establishment of interaction between 
Hib, or NTHi isolates and host cells and as an adhesin, by binding to laminin, fibronectin and collagen 
IV, which are components present on the respiratory epithelium. Additionally, considering the 
opportunistic behaviour of H. influenzae, Hap is also important for interaction and consequent 
invasion of damaged epithelium.97 Naturally, it is expected that other factors besides Hap, such as 
proteins D and E, may also contribute to invasion of the epithelium.70,71 
 
 
 
1.6. Biofilms 
 
 Biofilms are assemblies of microorganisms enclosed in a self-produced Extracellular 
Polymeric Substance (EPS) matrix, adhered to a surface.98 Changing from a planktonic to a biofilm 
state enables a multicellular behaviour that favours bacterial survival in unfavourable conditions.99 
Cell signalling (e.g.: quorum sensing) is a fundamental mechanism for bacterial communication and, 
ultimately, biofilm production.100  
Biofilm production is a dynamic process divided in three main stages. The first is adhesion 
and involves attachment to a surface, plus formation of microcolonies. The second phase is maturation 
of biofilm, which involves an adaptation to conditions of the surrounding environment and the 
production of an EPS matrix. The final stage is biofilm dispersion that can be triggered by different 
factors, such as nutrient availability, or antibiotic action, among others (Fig.1.5).99 
Attachment may occur on any surface – whether biotic, or abiotic – such as host tissues, or 
medical devices. Biofilms that may be a source of infection for humans pose a major concern of public 
health, since the presence of biofilms in humans constitutes a major virulence behaviour, being mostly 
associated with chronic infections (e.g.: recurrent OM, CSOM, pneumonia, cystic fibrosis, 
endocarditis and osteomyelitis). Biofilms serve as a protection mechanism for bacteria and can be 
repeatedly produced.100,101 Bacteria commonly associated with biofilms include Escherichia coli, 
Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus epidermidis, Enterobacter cloacae 
and Klebsiella pneumoniae. Biofilms formed by these bacteria are related to several human infections 
of the urinary tract, respiratory tract and soft tissue, for instance. Most of these bacteria are associated 
with hospital-acquired infections.101 
Challenges related to biofilm production include spreading of bacteria to bloodstream, causing 
secondary infections, resistance to antibiotics in the presence of a mature biofilm and, ultimately, 
recurrence of infection.101,102 Furthermore, routine bacterial cultures are designed to detect planktonic 
bacteria, meaning that these methods are less sensitive in detecting bacteria inside a biofilm. This may 
lead to false negative cultures.103 
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As referred, bacteria in biofilms usually present increased resistance to drug treatment. 
Resistance may come from hampering the penetration of biofilm, or from inhibition mechanisms 
through the action of enzymes (e.g.: β-lactamases), for instance, that inactivate antibiotics and protect 
bacteria.101,102 Therefore, the conventional use of antibiotics may not be efficient in these cases and 
surgical interventions, or alternative therapies that directly target the EPS matrix, or inhibition of 
quorum sensing signalling molecules, for example, have to be considered.100 
 
 
 1.6.1. H. influenzae biofilms 
 
 Until recently, H. influenzae biofilms were a topic of controversy, as to whether isolates were 
able to produce an EPS matrix and its significance for virulent behaviour.12,104 However, studies have 
shown a capacity of H. influenzae to aggregate in biofilms, which affect bacterial virulence.105  
 Considering that attachment is the first step towards biofilm production, various studies have 
focused on inhibiting bacterial adhesion, thus preventing biofilm production.99 
Several virulence factors expressed by H. influenzae were suggested to contribute to adhesion 
and to be constituents of the EPS matrix, including LOS, PilA, OMPs, HMW1 and HMW2 proteins. 
Jurcisek and Bakaletz106 have described the presence of dsDNA, LOS, OMPs and type IV pilin 
structures in the EPS matrix of NTHi biofilm. They hypothesised that pilin proteins may have a 
fundamental role in the structural stabilization of the biofilm, as interbacterial bridges. The fact that a 
PilA-mutant isolate could not form a biofilm as robust as isolates expressing this protein and that it 
presented a decreased adherence to the middle ear of a chinchilla host, further supported this 
statement. Similar to what has been reported for other bacterial biofilms,99 these authors106 described a 
compartmentalization of the EPS matrix constituents with dsDNA being mostly located in the outer 
edges of the biofilm. This possibly served for stabilization of the structure. A more recent study further 
Figure 1.5 | Schematic presentation of the three main stages of biofilm production: adhesion, maturation 
and dispersal (adapted from99). 
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supported such results, since antisera treatment targeting PilA protein translated into a significant 
inhibition of biofilm production by NTHi isolates.107  
Furthermore, HMW1 and HMW2 are thought to be major constituents of H. influenzae 
biofilms, as well, since antisera specific for these proteins has been shown to cover most of NTHi 
biofilm surface, suggesting a wide distribution of the adhesins on the EPS matrix.108   
Biofilms are known to provide protection against antibiotics, as previously referred. In the 
specific case of H. influenzae, in vitro studies have demonstrated a diminished effect of antibiotics 
against bacteria inside a biofilm. In fact, for the same bacterial isolate, the required antibiotic 
concentration to inhibit bacterial growth in a biofilm may be 100 folds higher than the dose required to 
inhibit the planktonic form.109 These results demonstrate that, in a biofilm associated infection, a 
patient may receive an empirical treatment that may, ultimately, have no effect, leading to bacterial 
survival and persistence of infection. The fact that routine culture methods may not detect bacteria 
inside biofilms and that there are no standard methods of antibiotic susceptibility tests for bacteria in 
biofilms, further hampers a proper treatment of infection.102,103 Moreover, it has been suggested that 
sub-inhibitory concentrations of β-lactams – the antibiotics most commonly used to treat H. influenzae 
infections – may actually induce biofilm production of NTHi isolates.110  
 An additional challenge related to biofilm production is the development of polymicrobial 
biofilms in infected tissues, resulting from interplay of different bacterial species. H. influenzae, for 
example, has been shown to form polymicrobial biofilms with Moraxella catarrhalis and 
Streptococcus pneumoniae.111,112    
When compared to biofilms formed by H. influenzae alone, in vitro and in vivo polymicrobial 
biofilms with Moraxella catarrhalis protected susceptible H. influenzae isolates against ampicillin and 
trimethoprim-sulfamethoxazole action, allowing an increase of the number of viable bacteria inside 
the biofilm. Furthermore, it was demonstrated that quorum sensing was fundamental for polymicrobial 
biofilm production, as previously described, since a quorum signalling-deficient H. influenzae isolate 
hampered biofilm production and bacterial persistence within it.111 Polymicrobial biofilm of H. 
influenzae and Streptococcus pneumoniae may lead to several phenotypes that enhance a capacity for 
both adaptability and persistence. For instance, different combinations of gene expression, that result 
in variations of surface proteins, are mechanisms that might be affected by the interaction between 
these two bacterial species and may help in the adhesion/cohesion of biofilms.112  
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 1.6.2. H. influenzae biofilms in patients with COPD and OM infections 
 
 Although several studies have demonstrated the capacity of H. influenzae isolates from 
patients with both COPD and OM to form biofilms, only a limited number of these have established 
comparisons between biofilm production and underlying diseases and, even so, the results of these 
studies may be contradictory.105,113-119 
Puig and colleagues105,114 have shown that isolates recovered from patients with OM tend to 
form denser biofilms than isolates collected from patients with lower respiratory tract diseases, such as 
COPD or Community Acquired Pneumonia (CAP). Additionally, the authors showed that biofilms 
formed by isolates from healthy carriers presented similar biofilm production to that of patients with 
lower respiratory tract diseases. One of these studies,114 further demonstrated that OM and invasive 
NTHi isolates possessed a higher and faster capacity for adherence than COPD and CAP isolates. 
Together, these studies could establish a correlation between disease and capacity for biofilm 
production.  
However, a different study conducted by Obaid and colleagues,119 which included isolates 
from patients with different clinical backgrounds (OM, conjunctivitis, lower respiratory tract diseases, 
cystic fibrosis and oropharyngeal normal flora) found no relation between clinical source and biofilm 
production. These results were in agreement with findings from Murphy and Kirkham,113 who 
compared OM and COPD isolates and also found that biofilm production was not related with the 
clinical group of isolates. 
 
 
 
1.7. Aim of the work 
 
H. influenzae is a commensal human-restricted microorganism of the nasopharynx. Due to its 
opportunistic behaviour, it is frequently associated with infections of the upper and lower respiratory 
tract. 
This work aimed to characterize non-invasive NTHi isolates recovered from patients with 
COPD and OM. Antibiotic susceptibility, genetic diversity and relatedness and assessment of the 
presence/absence of six virulence genes were performed with the final goal of establishing a 
relationship between these factors and the respective disease. The ability to assemble biofilms was 
assessed in order to explore a possible correlation between the studied diseases and the presence of 
virulence genes (pilA and hmw1A/2A) known to influence biofilm production.  
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2. Methods 
 
 
2.1. Clinical isolates 
 
 Isolates used in this Master Thesis belong to the collection of the “Laboratório Nacional de 
Referência de Infeções Respiratórias” in the “Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA)”, 
Lisboa and were collected between the years of 2013 and 2018. 
 A total of 93 isolates were included in the study. These were collected from patients with two 
non-invasive diseases: COPD and OM. Bacterial isolates were recovered from 10 Portuguese 
hospitals. Overall, 64.5% (60/93) isolates were from men and 35.4% (33/93) from women. Ages for 
COPD patients ranged from 50 to 89 years old and, for OM patients, from four months to 21 years old 
(Table 2.1). 
The thirty-eight H. influenzae isolates recovered from patients with COPD and the 55 isolates 
collected from patients with OM were analysed regarding capsular typing, ability to produce β-
lactamase, susceptibility to 12 antibiotics, genetic diversity, presence/absence of six virulence genes 
and ability for producing biofilms.  
Data regarding isolation date, gender of the respective patient, β-lactamase production, 
presence/absence of a capsule, presence/absence of the six virulence factors and biofilm production 
after 24h and 48h is detailed for each isolate on Tables 5.1 and 5.2 of the Appendix. 
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Table 2.1 | Sample characterization. 
Disease 
 
Epidemiological data 
COPD 
(n=38) 
n (%) 
OM 
(n=55) 
n (%) 
Total 
(n=93) 
n (%) 
Hospital 
North 19 (50.0%) 22 (40.0%) 41 (44.1%) 
Centre 17 (44.7%) 3 (5.5%) 20 (21.5%) 
Lisboa 2 (5.3%) 4 (7.3%) 6 (6.5%) 
Alentejo 0 25 (45.5%) 25 (26.9%) 
Açores and Madeira 
islands 
0 1 (1.8%) 1 (1.1%) 
Isolation Date 
2013 5 (13.2%) 14 (25.5%) 19 (20.4%) 
2014 3 (7.9%) 18 (32.7%) 21 (22.6%) 
2015 11 (28.9%) 5 (9.1%) 16 (17.2%) 
2016 7 (18.4%) 0 7 (7.5%) 
2017 11 (28.9%) 16 (29.1%) 27 (29.0%) 
2018 1 (2.6%) 2 (3.6%) 3 (3.2%) 
Age in Years 
<1 0 15 (27.3%) 15 (16.1%) 
1 - 4 0 36 (65.5%) 36 (38.7%) 
5 - 9 0 1 (1.8%) 1 (1.1%) 
10 - 25 0 2 (3.6%) 2 (2.2%) 
50 - 59 5 (13.2%) 0 5 (5.4%) 
60 - 69 8 (21.1%) 0 8 (8.6%) 
70 - 80 13 (34.2%) 0 13 (14.0%) 
≥80 12 (31.6%) 0 12 (12.9%) 
Gender 
Male 32 (84.2%) 28 (50.9%) 60 (64.5%) 
Female 6 (15.8%) 27 (49.1%) 33 (35.4%) 
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2.2. Bacterial growth and conservation 
 
Bacteria were grown on chocolate agar plates supplemented with polivitex (bioMérieux) and 
then incubated, for 18–24h, at 35ºC in a 5% CO2 atmosphere. 
 
H. influenzae isolates were stored in Tryptic Soy Broth (TSB) with 20 % glycerol at -80 ºC. 
 
 
2.3. DNA extraction 
 
 DNA extraction was performed by a boiling procedure: six to eight colonies were suspended 
in 100 µL of nuclease free ultra-pure water. The sample was boiled for 10 minutes (VWRTM – VMS-
C7), in order to disrupt the membranes of bacterial cells and was then centrifuged for 3 minutes at 
13000 rpm (eppendorf® – Centrifuge 5418). The supernatant, which contained the DNA, was stored at 
-20ºC.   
 
 
2.4. Antimicrobial susceptibility testing 
   
 
 2.4.1. β-lactamase production 
  
β-lactamase production was determined by a chromogenic cephalosporin assay: five to seven 
colonies of bacteria were suspended in 30 µL of nitrocefin (OXOIDTM – Nitrocefin Solution, 1mg). If a 
change in colour, from yellow to red, was observed, it was an indicative of a positive result 
(production of β-lactamase).120  
 
 
 2.4.2. Minimum Inhibitory Concentration  
 
Minimum Inhibitory Concentration (MIC) was determined for 12 antibiotics: Ampicillin 
(Am), Amoxicillin-clavulanate (Aug), Cefuroxime (Crm), Cefotaxime (Cft), Cefepime (Cpe), 
Meropenem (Mer), Azithromycin (Azi), Tetracycline (Te), Ciprofloxacin (Cp), Chloramphenicol (C), 
Rifampicin (Rif), and Trimethoprim/Sulfamethoxazole (T/S). 
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Commercial microdilution panels (Beckman Coulter – MICroSTREP Plus) were used to 
determine MICs, according to supplier’s instructions. 
In brief, 4 to 5 colonies of bacteria were suspended in 3 mL of sterile water (Beckman 
Coulter). Turbidity was compared to that of 0.5 of the McFarland barium sulphate standard 
(bioMérieux). Then, 100 µL of the suspension were added to 25 mL of Haemophilus Test Medium 
(Beckman Coulter). Suspension (200 µL) was poured into the 96-well microplate with the different 
antibiotic concentrations (Table 2.2) and was incubated at 35 ºC for 18 to 24 h in a non-CO2 incubator. 
MICs for each isolate were registered on a panel worksheet, as shown in Fig. 5.1 of the Appendix. 
 
Table 2.2 | Antibiotic concentrations on the microdilution panels. 
Antibiotic Concentrations of Antibiotic (mg/L) 
Am 0.03 0.06 0.12 0.25 0.5 1 2 4 8 
Cft 0.03 0.06 0.12 0.25 0.5 1 2 4 8 
Crm 0.25 0.5 1 2 4 8     
Te 1 2 4           
Rif 0.5 1 2           
Mer 0.06 0.12 0.25 0.5 1 2 4   
Aug 0.25/0.12 0.5/0.25 1/0.5 2/1 4/2       
C 1 2 4 8         
T/S 0.25/4.75 0.5/9.5 1/19 2/38         
Cpe 0.12 0.25 0.5 1 2       
Cp 0.06 0.12 0.25 0.5 1 2     
Azi 0.25 0.5 1 2 4       
 
 
2.5. Capsular typing 
 
 
 2.5.1. Amplification 
 
 Capsular typing, by PCR, was previously described by Falla and colleagues.20  
The reaction mix, with a final volume of 25 µL, was composed as follow: 15.85 µL of pure bi-
distilled water, 2.5 µL of 10x buffer (Qiagen), 2.5 µL of 10 mM dNTPs (dATP, dTTP, dCTP and 
dGTP, Roche, 2.5 µM each), 0.4 µL of each of the primers (forward and reverse) (Thermo Fisher 
Scientific, 10 µM), 1.75 µL of 25 mM MgCl2 (Qiagen), 0.1 µL of Taq DNA polymerase (Qiagen, 5 
U/µL) and 1.5 µL of DNA. 
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A positive and a negative control were included in the PCR.  
Sequences of the primers and the expected length of the amplified product are presented on 
Table 5.3 of the Appendix. PCR was conducted in a thermocycler (Applied Biosystems – GeneAmp® 
PCR System 9700) and the protocol is schematically presented on Table 2.3. 
 
Table 2.3 | Capsular typing PCR protocol. 
 
Temperature Time Cycles 
Denaturation 940C 5 min 1 
Denaturation 940C 1 min 
 
Annealing 550C 1 min 30 
Extension 72oC 1 min   
Final extension 72oC 10 min 1 
Conservation 4oC  ∞ 
 
 
  
2.5.2. Analysis of fragments by gel electrophoresis 
 
 Analysis of the results was conducted by observing the presence/absence of bands of the 
amplified gene fragment in a 2% (w/v) agarose (Lonza - SeaKem®LE Agarose) gel in Tris-Borate-
EDTA 1x (TBE 1x). The gel contained 5% of Sybr Safe (Roche), in order for the bands to be visible in 
a UV-transilluminator (BioRad – Gel DocTM XR). Electrophoresis was conducted for 30 minutes at 100 
V.  
Molecular weight marker VIII (Roche Diagnostics GmbH), which presents standard bands 
between 19 and 1114 pb, was used for band weight comparison. 
 Before loading the samples in the gel, 7 µL of each sample were added to 3 µL of loading 
buffer (0.25 % bromophenol blue, 0.25% cyanol xilene and 50% glycerol, in water).  
 
 If an isolate was encapsulated, a band with, approximately, 343 bp should be visible.  
In order to characterize the capsule type, a second PCR should be performed. In this case, 
specific primers (Eurogentec Gold, 10 µM) for each capsular type were used. PCR serotyping protocol 
was the same as described in 2.5.1. section. Sequences of the primers and the expected length for the 
amplified products are presented on Table 5.3 of the Appendix. 
 
 
 
 
Haemophilus influenzae in Chronic Obstructive Pulmonary Disease and Otitis Media 
28 
 
2.6. Multilocus Sequence Typing  
 
 
2.6.1. Amplification 
 
MLST protocol was previously described by Meats and colleagues.23  
Seven housekeeping genes were amplified for each H. influenzae isolate: adK, atpG, frdB, 
fucK, mdh, pgi and recA. 
For each allele, a reaction mix with a final volume of 25 µL was constitute as follow: 12.5 µL 
of HotStart Taq DNA Polymerase master mix (Qiagen), 1 µL of the specific primer, forward and 
reverse (Thermo Fisher Scientific, 20 µM), 5.5 µL of nuclease free water (Qiagen) and 5 µL of DNA.  
Sequences of the primers and the expected length for the amplified product are presented on 
Table 5.4 of the Appendix. PCR was conducted in a thermocycler (Applied Biosystems – GeneAmp® 
PCR System 9700) and the protocol is schematically presented on Table 2.4. 
 
 
Table 2.4 | MLST amplification protocol. 
 
Temperature Time Cycles 
Denaturation 950C 15 min 1 
Denaturation 950C 0:30 min 
 
Annealing 470C 0:30 min 34 
Extension 72oC 1 min   
Final extension 72oC 10 min 1 
Conservation 4oC  ∞ 
 
  
 
2.6.2. Purification  
 
 Purification protocol was performed as described by Applied Biosystems by Thermo Fisher 
Scientific.121 
 Each amplification product (5 µL) was added to 2 µL of ExoSAP-IT™ PCR Product Cleanup 
Reagent (Thermo Fisher Scientific).  
PCR was conducted in a thermocycler (Applied Biosystems – GeneAmp® PCR System 9700) 
and the protocol is schematically presented on Table 2.5. 
Samples were loaded into a 2% (w/v) agarose gel in TBE 1x, to verify amplification and 
purification of all seven housekeeping genes, as described in 2.5.2. section. 
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Table 2.5 | Purification PCR protocol. 
Temperature Time Cycles 
370C 15 min 1 
800C 15 min 1 
4oC  ∞   
 
 
2.6.3. Sequencing 
 
 After purification, 1 µL of each purified product was added to a mix, containing 4 µL of 
nuclease and protease free water, 3.2 µL of 5x Big Dye Buffer (Applied Biosystems), 0.8 µL of Big 
Dye (Applied Biosystems) and 1 µL of M13 Phage forward primer (invitrogen, 20 µM).  
PCR was conducted in a thermocycler (Applied Biosystems – GeneAmp® PCR System 9700) 
and the protocol is schematically presented on Table 2.6. 
 
Table 2.6 | Sequencing PCR protocol. 
 
Temperature Time Cycles 
Denaturation 960C 0:30 min 1 
Denaturation 960C 0:10 min   
Annealing 500C 0:05 min 25 
Extension 60oC 4 min   
Conservation 4oC  ∞ 
 
 
 
Samples were forwarded to the “Unidade de Tecnologia e Inovação” from the “Departamento 
de Genética Humana”, in INSA, where sequencing was performed, by capillary electrophoresis, in a 
genetic analyser (Applied Biosystems – ABI 3130XL). 
 
 
 2.6.4. Multilocus Sequence Typing analysis 
 
 After sequences for the seven alleles of each isolate were obtained, these were analysed by the 
Finch TV software. A FASTA document was created for each sequence and uploaded to the 
Haemophilus influenzae database (http://pubmlst.org/hinfluenzae/). Each sequence of the seven 
housekeeping genes were compared with the same locus sequences in the database.  
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If the sequence matched a previously assigned allele, the same allele number was attributed. If 
the sequence did not match any allele, it was necessary to submit the sequence to the database for 
assignment of a new allele number. When the combination of the numbers for the seven alleles 
matched a combination in the database, a ST number was attributed to the isolate. In the case of a new 
combination of the STs for the seven alleles, all seven allele numbers had to be submitted to the 
database for assignment of a new ST number.  
To display allelic differences between obtained STs, goeBURST analysis was performed using 
PHYLOViZ platform. STs that differed in one, two, or three genes were identified as Single Locus 
Variant (SLV), Double Locus Variant (DLV) and Triple Locus Variant (TLV), respectively. A 
Minimum Spanning Tree (MTS) presenting STs as nodes was obtained and STs would be joined if 
these were related up to DLV. 
 
 
2.7. Virulence factors 
 
 Analysis of the presence/absence of six virulence genes was based on the protocols previously 
described by Vuong and colleagues (for pilA, ompP5, hmw1A, hmw2A),78 Geluk and colleagues (for 
hifA),82 and Cardines and colleagues (for hia).89 Original protocols were adapted, in order to reduce 
unspecific amplified products. 
 The reaction mix, with a final volume of 22.5 µL, was composed as follow: 12.7 µL of pure 
bi-distilled water, 5 µL of 5x Buffer (Promega), 1 µL of 10 mM dNTPs (Roche), 1 µL of each primer, 
forward and reverse (Invitrogen, 20 µM) specific for each gene, 1.5 µL of 25 mM MgCl2 (Promega), 
0.2 µL of GO Taq® DNA polymerase (Promega, 5 U/µL) and 2.5 µL of DNA. This master mix was 
common to all analysed genes, except for hia gene, for which 0.15 µL of Ex Taq (Takara, 5 U/µL) 
was used.  
A positive and a negative control were included in the PCR.  
Sequences of the primers and the expected length of the amplified products are presented on 
Table 5.5 of the Appendix. PCR was conducted in a thermocycler (Applied Biosystems – GeneAmp® 
PCR System 9700) and the protocol is schematically presented on Table 2.7 for pilA, Table 2.8 for 
hifA, Table 2.9 for hmw1A/2A, Table 2.10 for hia and Table 2.11 for ompP5. 
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Table 2.7 | pilA PCR protocol. 
 
Temperature Time Cycles 
Denaturation 940C 5 min 1 
Denaturation 940C 1 min 
 
Annealing 500C 0:30 min 35 
Extension 72oC 1:30 min   
Final extension 72oC 5 min 1 
Conservation 4oC  ∞ 
 
 
 
 
Table 2.8 | hifA PCR protocol. 
 
Temperature Time Cycles 
Denaturation 94ºC 5 min 1 
Denaturation 95ºC 1 min 
 
Annealing 55ºC 1 min 35 
Extension 72ºC 2 min   
Final extension 72ºC 8 min 1 
Conservation 4oC  ∞ 
 
 
 
 
Table 2.9 | hmw1A/2A PCR protocol. 
 
Temperature Time Cycles 
Denaturation 940C 5 min 1 
Denaturation 940C 1 min 
 
Annealing 520C 0:30 min 35 
Extension 72oC 1 min   
Final extension 72oC 10 min 1 
Conservation 4oC  ∞ 
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Table 2.10 | hia PCR protocol. 
 
Temperature Time Cycles 
Denaturation 95ºC 5 min 1 
Denaturation 95ºC 1 min 
 
Annealing 53ºC 1 min 30 
Extension 72ºC 5 min   
Final extension 72ºC 10 min 1 
Conservation 4oC  ∞ 
 
 
 
 
Table 2.11 | ompP5 PCR protocol. 
 
Temperature Time Cycles 
Denaturation 94ºC 5 min 1 
Denaturation 94ºC 0:30 min 
 
Annealing 53ºC 0:30 min 35 
Extension 72ºC 2 min   
Final extension 72ºC 10 min 1 
Conservation 4oC  ∞ 
 
 
 
 Samples were loaded into a 2% (w/v) agarose gel in TBE 1x, to verify if all samples contained 
the amplified product, as described in 2.5.2. section. Molecular weight marker VII (Roche Diagnostics 
GmbH) which presents standard bands between 359 and 8576 bp, was used for analysis of hia gel 
bands, while molecular weight marker VIII (bands between 19 and 1114 bp) was used for analysis of 
the remaining genes. 
 
 
2.8. Biofilms 
 
 Regarding biofilm production, in addition to the 93 NTHi isolates, 14 invasive isolates were 
included in this study. Invasive isolates had been previously analysed by Whole Genome Sequencing 
(WGS) and were selected as positive controls for possessing hmw1A/2A genes, which have been 
associated with biofilm production. Invasive isolates comprised the years 2002, 2006, 2008–2012, 
2014–2016 and were all NTHi. 
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Biofilm formation protocol was based on the modified Christensen’s method with small 
modifications.122  
 The assay was conducted using 96-well flat-bottomed cell culture plates (Thermo Scientific 
– Nunc™) with four replicates for each isolate and negative control. Briefly, bacterial suspensions 
were prepared in saline to a final concentration of, approximately, 108 CFU/mL (OD600 nm = 0.2 
[Thermo Scientific – GENESYSTM 20]) from H. influenzae isolates grown overnight in chocolate agar 
plates. Bacterial suspensions were diluted in Brain Heart Infusion (BHI) broth (1:10) for a final 
volume of 200 µL and distributed in each well. BHI broth was used as negative control. Plates were 
incubated, at 37 ºC, for 24h and 48h (Thermo Scientific – HERAThermTM). Each well was, then, 
aspirated and all wells were washed three times with sterile distilled water, for removal of non-
adherent bacteria. Attached bacteria were stained with 100 µL of crystal violet for 15 min at room 
temperature. After crystal violet was removed, each well was washed three times with sterile distilled 
water. To each well, 200 µL of 96% ethanol were added, to elute crystal violet. Optical density was 
measured at an OD570 nm in a microplate reader (Thermo Labsystems – Multiskan AscentTM). 
  
Biofilm formation by H. influenzae was classified as described by Stepanović and 
colleagues.123  
 A mean OD570 nm for each isolate (ODisolate) plus the negative control (ODnc) replicates and 
standard deviation (SD) were calculated. Cut-off for biofilm formation (ODcut-off) was defined as the 
mean of the negative control adding to 3 times the respective SD (SDnc) (ODcut-off = ODnc + 3SDnc).  
Isolates were classified as non-producers, weak, moderate and strong biofilm producers, 
according to the criteria described in Table 2.12. 
 
Statistical significance of the obtained results was evaluated by the chi-square test, where a p 
value inferior to 0.05 (p < 0.05) was regarded as statistically significant.  
 
 
Table 2.12 | Criteria for classification of H. influenzae isolates ability to assemble biofilms. 
Classification OD Range 
Non-producer ODisolate ≤ ODcut-off 
Weak producer ODcut-off < ODisolate ≤ 2ODcut-off 
Moderate producer 2ODcut-off < ODisolate ≤ 4ODcut-off  
Strong producer ODisolate > 4ODcut-off 
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3.1. Clinical isolates
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Table 3.1 | Antibiotic breakpoints for H. influenzae. 
Antibiotic 
Susceptible 
(mg/L) 
Intermediate 
(mg/L) 
Resistant 
(mg/L) 
Am ≤ 1 - > 1 
Cft ≤ 0.125 - > 0.125 
Crm (oral) ≤ 0.125 0.125 – 1 > 1 
Te ≤ 1 1 – 2 > 2 
Rif (for prophylaxis only) ≤ 1 - > 1 
Mer (indications other than meningititis) ≤ 2 - > 2 
Aug ≤ 2 - > 2 
C ≤ 2 - > 2 
T/S ≤ 0.5 0.5 – 1 > 1 
Cpe ≤ 0.25 - > 0.25 
Cp ≤ 0.06 - > 0.06 
Azi* ≤ 0.125 0.125 – 4 > 4 
*For azithromycin, 2017 EUCAST breakpoints were used 
 
 
Tables 3.2 and 3.3 show the MIC50, MIC90, MIC range and percentage of susceptible, 
intermediate and resistant isolates for COPD and OM isolates, respectively. 
The majority of both COPD and OM isolates was susceptible to all 12 tested antibiotics. 
Among COPD isolates, resistance to ampicillin was verified for 15.8% (6/38) of isolates, all of 
which were β-lactamase producers. Resistance was also observed for cefuroxime (8/38, 21.1%), 
trimethoprim/sulfamethoxazole (11/38, 28.9%), ciprofloxacin (1/38, 2.6%) and azithromycin (1/38, 
2.6%) (Table 3.2). It should be noted that H. influenzae resistance to ciprofloxacin was characterized 
for the first time in the laboratory (MIC > 32 mg/L, by E-test). 
Intermediate resistances to cefuroxime and azithromycin were identified. Regarding 
cefuroxime, 71.0% (27/38) isolates were considered intermediate. For azithromycin, the lowest 
concentration tested was 0.25 mg/mL. The 2017 susceptible breakpoint was ≤ 0.125 mg/L. 
Considering that MIC50 and MIC90 for this antibiotic were 0.5 and 2 mg/mL, respectively, all COPD 
isolates with a breakpoint inferior to 4 mg/mL (37/38, 97.4%) were classified as intermediate (Table 
3.2). 
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Table 3.2 | Antibiotic susceptibility of COPD isolates. 
 
COPD (n=38) 
Antibiotic 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
MIC range 
(mg/L) 
Susceptible 
n (%) 
Intermediate 
n (%) 
Resistant 
n (%) 
Am 0.25 >8 0.12 – >8 32 (84.2%) 0 6 (15.8%) 
Cft ≤0.03 ≤0.03 ≤0.03 – 0.12 38 (100%) 0 0 
Crm 0.5 2 ≤0.25 – 4 3 (7.9%) 27 (71.0%) 8 (21.1%) 
Te ≤1 ≤1 – 38 (100%) 0 0 
Rif ≤0.5 ≤0.5 – 38 (100%) 0 0 
Mer ≤0.06 0.12 ≤0.06 – 0.25 38 (100%) 0 0 
Aug 0.5 2 ≤0.25 – 2 38 (100%) 0 0 
C ≤1 ≤1 – 38 (100%) 0 0 
T/S ≤0.25 >2 ≤0.25 – >2 27 (71.1%) 0 11 (28.9%) 
Cpe ≤0.12 0.25 ≤0.12 – 0.25 38 (100%) 0 0 
Cp ≤0.06 ≤0.06 ≤0.06 – >2 37 (97.4%) 0 1 (2.6%) 
Azi* 0.5 2 ≤0.25 – >4 0 37 (97.4%) 1 (2.6%) 
*For azithromycin, 2017 EUCAST breakpoints were used 
 
 
Among OM isolates, 18.2% (10/55) of isolates were considered resistant to ampicillin. Eight 
of these were β-lactamase producers, while the remaining two were non-β-lactamase producers. Of the 
non-producers, one was considered resistant to amoxicillin-clavulanate (MIC=4 mg/mL), the other 
intermediate (MIC=2 mg/mL) and both isolates presented reduced susceptibility to other β-lactam 
antibiotics. Considering these, both isolates were phenotypically identified as BLNAR. Resistance 
rates were observed for cefuroxime (11/55, 20.0%), trimethoprim/sulfamethoxazole (14/55, 25.5%), 
cefepime (2/55, 3.6%) and azithromycin (1/55, 1.8%), as well (Table 3.3).  
Thirty-five (35/55, 63.6%) isolates were considered intermediate to cefuroxime. Similar to the 
results for COPD isolates, MIC50 and MIC90 of azithromycin for OM isolates were 1 and 2 mg/mL, 
respectively and 54/55 (98.2%) isolates were considered intermediate (Table 3.3). 
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Table 3.3 | Antibiotic susceptibility of OM isolates. 
 
OM (n=55) 
Antibiotic 
MIC50 
(mg/L) 
MIC90 
(mg/L) 
MIC range 
(mg/L) 
Susceptible 
n (%) 
Intermediate 
n (%) 
Resistant 
n (%) 
Am 0.25 >8 0.06 – >8 45 (81.8%) 0 10 (18.2%) 
Cft ≤0.03 ≤0.03 ≤0.03 – 0.06 55 (100%) 0 0 
Crm 0.5 4 ≤0.25 – 8 9 (16.4%) 35 (63.6%) 11 (20.0%) 
Te ≤1 ≤1 – 55 (100%) 0 0 
Rif ≤0.5 ≤0.5 – 55 (100%) 0 0 
Mer ≤0.06 0.12 ≤0.06 – 1 55 (100%) 0 0 
Aug 0.5 1 ≤0.25 – 0.5 54 (98.2%) 0 1 (1.8%) 
C ≤1 ≤1 – 55 (100%) 0 0 
T/S ≤0.25 >2 ≤0.25 – >2 41 (74.5%) 0 14 (25.5%) 
Cpe ≤0.12 0.25 ≤0.12 – 0.5 53 (96.4%) 0 2 (3.6%) 
Cp ≤0.06 ≤0.06 – 55 (100%) 0 0 
Azi* 1 2 ≤0.25 – >4 0 54 (98.2%) 1 (1.8%) 
*For azithromycin, 2017 EUCAST breakpoints were used 
 
 
3.4. Multilocus Sequence Typing 
 
 Forty-one isolates – 16 COPD and 25 OM isolates – were analysed by MLST. Isolates were 
selected according to date of collection and antibiotic susceptibility pattern: (i) all isolates collected in 
2017 and 2018 and (ii) all β-lactamase producers. Besides these, MLST was also performed for the 2 
BLNAR, the ciprofloxacin resistant and the serotype f isolates. 
 Overall, 31 different STs were assigned (31/41, 75.6%). Five of these, were new STs: 1894, 
1895, 1896, 1900 and 1901. All new STs belonged to OM isolates, with the exception of ST 1901, 
which belonged to a COPD isolate (Table 3.4).  
 
 
 
 
 
 
 Beatriz da Cunha Batista 
41 
 
Table 3.4 | New STs assigned during the course of this project.  
H.influenzae ID Year Diagnosis adk atpG frdB fucK mdh pgi recA ST 
13692 2017 OM 69 20 7 1 26 36 29 1894 
13741 2017 OM 63 32 7 1 46 74 29 1895 
13744 2017 OM 39 8 53 11 65 48 19 1896 
12880 2013 OM 3 54 65 1 64 82 48 1900 
13776 2017 COPD 5 8 58 14 46 13 29 1901 
 
 
 A schematic presentation of isolates genetic diversity is shown in Fig. 3.4, where isolates that 
differed up to two alleles (DLVs) were joined together. STs exclusive to each clinical group – COPD, 
or OM – were separated according to the respective group. STs shared among both COPD and OM 
isolates were presented between the two groups. 
It was verified a high genetic diversity among NTHi isolates, with 31 different STs assigned to 
41 analysed isolates. Serotype f isolate was characterized as ST=124. 
 There were COPD and OM isolates with the same STs: 155, 389, 103 and 1218. STs 155, 389 
and 1218 were shared among two isolates, each: one COPD and one OM. ST 103 was shared among 
three isolates: one COPD and two OM.  
STs 155 and 1281, 1218 and 107 and 1521 and 196 differed in two alleles. STs 474 and 1900 
only differed in one allele. 
 Four STs were assigned to isolates belonging to the same clinical group. Regarding COPD 
isolates, STs 170 and 388 were both shared among two isolates. In relation to OM isolates, ST 57 was 
shared among three isolates and ST 241 was shared among two isolates. ST 57 was the most prevalent 
among OM isolates. 
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Figure 3.4 | Schematic presentation of genetic diversity among H. influenzae isolates (PHYLOViZ 2.0©, 
with goeBURST algorithm). Thirty-one STs are indicated by numbers within circles. Colours were attributed 
to each ST number and are described in the Legend. The number (n) of isolates that belong to each ST is also 
described in the Legend. The size of the circle is proportional to the number of isolates that share that ST. STs 
were grouped according to the clinical group, COPD or OM. Four STs were shared among COPD and OM 
clinical groups. STs that presented up to DLVs were joined by dark lines, labelled with the number of allelic 
differences between STs.  
*new STs assigned during the present study  
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3.5. Virulence genes 
 
All 93 isolates were analysed for the presence of six virulence genes: pilA, hifA, hmw1A, 
hmw2A, hia and ompP5. 
 Presence of pilA was observed for the majority of both COPD (38/38, 100%) and OM isolates 
(51/55, 92.7%). Similarly, the presence of ompP5 was also verified for most COPD (31/38, 81.6%) 
and OM isolates (36/55, 65.5%) (Table 3.5). 
On the other hand, hifA and hia were present in less than 50% of either COPD (5.3% and 
13.2%, respectively), or OM isolates (25.5% and 41.8%, respectively). However, our results showed a 
higher prevalence of both hifA and hia genes in OM isolates, when compared to COPD isolates (Table 
3.5). 
 Regarding hmw1A and hmw2A genes, these were found together in the majority of COPD 
isolates (29/38, 76.3%) and in less than 50% of OM isolates (14/55, 25.5%). We highlight four OM 
isolates where hmw2A gene was found, in the absence of hmw1A gene, which turned in a higher 
prevalence of hmw2A gene (18/55, 32.7%), when compared with hmw1A gene (14/55, 25.5%), as 
presented on Table 3.5. 
 
Table 3.5 | Distribution of virulence genes in COPD and OM H. influenzae isolates.  
Gene            
                   
Disease 
pilA 
n (%) 
hifA 
n (%) 
hmw1A 
n (%) 
hmw2A 
n (%) 
hia 
n (%) 
ompP5 
n (%) 
COPD (n=38) 
38  
(100%) 
2 
(5.3%) 
29  
(76.3%) 
29 
 (76.3%) 
5 
(13.2%) 
31 
 (81.6%) 
OM (n=55) 
51  
(92.7%) 
14 
 (25.5%) 
14  
(25.5%) 
18 
 (32.7%) 
23  
(41.8%) 
36  
(65.5%) 
 
 
It was further observed, in both clinical groups, that hia gene was present only when both hmw 
genes were absent. 
Regarding COPD clinical group, it was verified that the majority of isolates (29/38, 76.3%) 
possessed both hmw genes, with absence of hia gene. Only 10.5% (4/38) of COPD isolates lacked all 3 
genes (Table 3.6). 
In opposite, in the OM clinical group, most isolates lacked both hmw genes and possessed hia 
gene (23/55, 41.8%). Curiously, the same number of isolates possessed both hmw genes and lacked 
hia (14/55, 25.5%), or lacked all 3 genes (14/55, 25.5%).  
It was further observed that in all four isolates that only possessed the hmw2A gene, hia gene 
was absent (Table 3.6).  
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Table 3.6 | Relation between hmw1A/2A and hia genes in COPD and OM H. influenzae isolates.  
Disease                                                   
Genes 
COPD (n=38)
n (%) 
OM (n=55) 
n (%) 
hmw1A/2A (+) / hia (-) 
29 
 (76.3%) 
14  
(25.5%) 
hmw1A/2A (-) / hia (+) 
5 
 (13.2%) 
23 
 (41.8%) 
hmw1A/2A (-) / hia (-) 
4 
 (10.5%) 
14 
 (25.5%) 
hwm2A (+) / hia (-) 0 
4 
 (7.3%) 
hmw2A (+) / hia (+) 0 0 
 
 
 
3.6. Biofilms 
 
 3.6.1. Biofilm production 
 
After 24h incubation, only 14.0% (15/107) of isolates were able to form a biofilm and after 
48h, this number had increased to 29.0% (31/107). Therefore, an overall increase of 15.0% in biofilm 
production was verified from 24h to 48h. Even so, the results suggested a lack of ability for more than 
50% of all isolates to form a biofilm after either 24h, or 48h incubation. Measurement of OD600nm at 
24h and 48h, enabled to conclude that the overall bacterial growth remained relatively stable after 
these incubation times.  
Results for biofilm production after 24h and 48h incubation and isolate classification 
regarding biofilm production, according to each clinical group, are summarized on Table 3.7 and 
schematically presented on Fig. 3.5.  
After 24h, the majority of isolates from the three clinical groups was not able to assemble a 
biofilm (92.1% [35/38], 81.8% [45/55] and 85.7% [12/14] of COPD, OM and invasive isolates, 
respectively). At 48h, this behaviour persisted for most of these isolates (71.4% [25/35], 86.7% 
[39/45] and 83.3% [10/12] of COPD, OM and invasive isolates, respectively) and only in a minority 
biofilm assembly was observed (17.1% [9/35], 13.3% [6/45] and 16.7% [2/12] of COPD, OM and 
invasive isolates, respectively). Even so, these biofilm assemblers fitted the category of weak 
producers. Only one COPD isolate (2.9%) became a moderate producer, after 48h incubation. 
Few COPD, OM and invasive isolates were weak biofilm producers after 24h (7.9% [3/38], 
16.4% [9/55] and 7.1% [1/14] of COPD, OM and invasive isolates, respectively) and while the 
majority of COPD isolates became moderate producers (66.7% [2/3]) most OM isolates persisted as 
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weak producers, after 48h (88.9% [8/9]). One OM (11.1% [1/9]) and the invasive isolate (7.1% [1/14]) 
became non-producers after 48h.  
None of COPD isolates were moderate biofilm producers after 24h. Only 1.8% (1/55) of OM 
and 7.1% (1/14) of invasive isolates were moderate producers after 24h incubation. After 48h, the OM 
isolate persisted as a moderate biofilm producer, while the invasive isolate became a weak biofilm 
producer. 
No isolates, in the three clinical sets, were strong biofilm producers after either 24h, or 48h. 
 
Although a relation between the production of biofilm and the respective clinical group could 
be identified, with OM isolates being most capable of biofilm production – mainly after 24h – 
followed by COPD and invasive isolates (Table 3.7 and Fig. 3.5), this association was not statistically 
significant (p = 0.342).  
Similar results were obtained for classification of isolates as weak and moderate biofilm 
producers. For example, it was possible to conclude that the majority of weak COPD producer isolates 
became moderate producers from 24h to 48h and that most weak OM isolates maintained as weak 
producers. However, classifications and correlation with each clinical group after 24h (p = 0.236) and 
48h (p = 0.339) did not meet statistical significance, as well. 
 
 
3.6.2. Virulence factors and biofilm production 
 
It was verified that all COPD and the majority of OM biofilm producer isolates possessed the 
pilA gene. The majority of COPD biofilm producer isolates also possessed hmw1A/2A genes. 
However, none of OM biofilm producers, after 24h, possessed these genes and few producers after 
48h incubation possessed both (n=2). Considering that most COPD and OM non-producer isolates, 
after either 24h or 48h, also possessed pilA and hmw1A/2A genes, it appears that no correlation could 
be established. Furthermore, very few invasive isolates produced a biofilm after 24h (n=2) and 48h 
(n=3). Since all of these isolates were known to possess hmw1A/2A genes, these results further suggest 
that a correlation could not be established. 
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Table 3.7 | Biofilm production at 24h and 48h and classification of isolates as weak and moderate 
producers, according to each clinical group.  
     Classification of biofilm producer isolates 
   Biofilm Production Weak Moderate   n (%) n (%) n (%) 
Pathology Biofilm (24h) Biofilm (48h) 24h 48h 24h  48h 
COPD 3 13 3 10 - 3 
(n=38) (7.9%) (34.2%) (7.9%) (26.3%) (7.9%) 
       OM 10 15 9 14 1 1 
(n=55) (18.2%) (27.3%) (16.4%) (25.5%) (1.8%) (1.8%) 
       Invasive 2 3 1 3 1 
- 
(n=14) (14.3%) (21.4%) (7.1%) (21.4%) (7.1%) 
Total 15 31 13 27 2 4 
(n=107) (14.0%) (29.0%) (12.1%) (25.2%) (1.9%) (3.7%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 | Biofilm production after 24h and 48h.   
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4. Discussion 
 
 
4.1. Haemophilus influenzae and non-invasive diseases 
  
H. influenzae has been long associated to invasive disease. Therefore, most worldwide 
epidemiological studies have focused on these infections.25,27,48,51,125-128 Similarly, in Portugal, 
epidemiology of invasive disease is published in three studies: one of the pre-vaccine era (1989-
2001)54 and two of the post-vaccine era (2002-201055 and 2010-201456). However, since H. influenzae 
is a commensal bacterium in the human nasopharynx, it is also responsible for triggering non-invasive 
infections that may be associated with diseases of the respiratory tract, such as COPD and OM.  
  
 
4.1.2. Chronic Obstructive Pulmonary Disease 
 
 Due to its chronic nature, COPD is a disease that usually affects adults over 40 years of age. In 
fact, a review that included data from 19 European countries showed that the mean age for COPD 
patients was 55.9 years old.129 Two other studies that analysed COPD data from six European 
countries and from USA, Mexico, Brazil, Russia, Japan and South Korea130,131 described a mean age 
ranging from 57.2 to 66.8 years old for COPD patients. An increase in prevalence of the disease with 
aging was also reported. Our results were in agreement with these findings, since all clinical isolates 
were recovered from patients with more than 50 years of age (Fig. 3.1), being the majority of these 
(36.8%) within the range of 75 to 84 years old. These were also in agreement with data from France 
and Spain, that also presented a higher rate of disease in the oldest population (70 years old, or 
older).130,131 The difference in age range between Portugal and reports for other countries may be 
related to geographical factors, tobacco smoking, environmental exposure and/or occupational 
exposure to pollution.  
Considering gender distribution, our data showed that males were the most affected gender 
(84.2%), with only a small percentage of isolates recovered from women (15.8%) (Table 2.1). These 
results are in agreement with previous reports for different countries,130 but recent data suggests that 
this disease may equally affect both genders, nowadays.32   
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4.1.3. Otitis Media 
 
 In opposite to COPD, OM is a disease that mostly affects children in the first years of life.41 
An epidemiological study,43 that collected worldwide data from all continents, indicated that 51% of 
annual AOM cases affected children under the age of five, with a higher global incidence in children 
with less than one and between one and four years old. Our results are in agreement with such data, 
since the majority of the isolates were recovered from children between the ages of less than one and 
three years old (85.5%), with a high percentage of cases in the first year of life (30.9%) (Fig. 3.2). 
Differences in gender were not observed, since 50.9% of the patients were male and 49.1% were 
female (Table 2.1). These results were in agreement with other studies that reported no risk factors and 
no significant differences associated with gender.132,133 
  
 
 
4.2. Capsular typing 
  
NTHi has been associated with infection in patients suffering from COPD, with or without 
exacerbations.34,134 Similarly, in patients suffering from OM, NTHi is one of the most common 
pathogens. It has been further demonstrated that a high prevalence of NTHi in children up to two years 
old, suffering from AOM, highlights the important infectious role of this bacteria.135 
In our study, all 55 OM isolates were characterized as NTHi, as well as all but one COPD 
isolate (37/38, 97.4%). This was expected, since COPD and OM have been extensively described as 
NTHi diseases.34,36,134,135,136 Since NTHi is an opportunistic commensal of the human nasopharynx, it 
can easily spread to the lower respiratory tract, causing infections in COPD patients, or it may spread 
to the middle ear to cause OM.136 
 
 
 
4.3. Antibiotic susceptibility 
 
 COPD and OM infections are often treated with antibiotics. In Portugal, guidelines from the 
“Direcção-Geral da Saúde” (DGS) recommend the use of a β-lactam (amoxicillin with, or without 
clavulanic acid), macrolides or doxycyclines for treatment of COPD exacerbations with sputum.39 For 
children with AOM, the first antibiotics to be recommended by DGS are amoxicillin/amoxicillin-
clavulanate, or cefuroxime in the case of ineffectiveness of the first antibiotics.44 However, an increase 
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of bacterial resistance against antibiotics has been observed over the last decades, which is a great 
concern.   
In the present study, the antibiotic that presented the highest percentage of resistance was 
trimethoprim/sulfamethoxazole. Our results showed that 28.9% and 25.5% of COPD and OM isolates, 
respectively, were resistant to trimethoprim/sulfamethoxazole (Table 3.2 and 3.3). These results were 
in accordance with the percentages described among 144 invasive H. influenzae isolates in the 
previous Portuguese study55 (20.4%) and among 482 NTHi invasive isolates in a Canadian study137 
(20.7%). Decreased susceptibility to trimethoprim/sulfamethoxazole was also reported for 54.4% of H. 
influenzae isolates, recovered from patients with respiratory tract infections, in China.138 Although 
trimethoprim/sulfamethoxazole is not an antibiotic commonly used in Portugal for treatment of either 
COPD, or OM infections,39,44 the resistance rate here identified may be related to its use for treatment 
of other infections, which may ultimately affect susceptibility of H. influenzae, in general.   
It is worth noting that, although it is not common, one COPD isolate was identified as resistant 
to ciprofloxacin. This was the first time that a H. influenzae isolate resistant to ciprofloxacin was 
characterized, in our laboratory, in approximately 4,500 isolates. A case study in USA139 reported a 
patient, suffering from a chronic lung disease, infected with a H. influenzae resistant to ciprofloxacin 
and presenting a MIC of 8 mg/L. The authors attributed resistance to a long exposure to the antibiotic, 
which was used for treatment of respiratory tract infections. Curiously, a 2015 Spanish study140 
reported 15 NTHi isolates, recovered from patients with respiratory infections, with ciprofloxacin 
MICs between 8 and 16 mg/L. The authors related this result with a common use of this antibiotic to 
treat respiratory infections. However, the authors reported that the percentage of ciprofloxacin 
resistant isolates remained low. Even so, this antibiotic is not recommended for treatment of COPD, or 
OM infections in Portugal, which could explain the presence of only one resistant isolate among the 
93 analysed isolates.39,44  
 
 
4.3.1. β-lactamase production 
 
In the present study, most isolates (84.9%) did not produce β-lactamase. Ampicillin resistance 
by β-lactamase production was identified in 15.8% and 14.5% of COPD and OM isolates, 
respectively, which accounted for 15.1% among a total of 93 characterized isolates (Fig. 3.3). The 
percentages for ampicillin-resistant β-lactamase producer COPD and OM isolates were slightly higher 
than that described for NTHi invasive isolates in the 2002-2010 study (12.6%),55 but similar to those 
obtained in a Spanish study with 349 NTHi isolates, recovered from patients with respiratory tract 
infections (15.8%).141 Due to the common use of β-lactams for treatment of  H. influenzae infections 
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(e.g.: COPD and OM) resistance to ampicillin has increased over the years, although resistance rates 
differ from different countries.62  
In fact, higher percentages were found in a Canadian study137 that reported 21.4% β-lactamase 
producers among NTHi invasive isolates. For NTHi isolates recovered from patients with COPD and 
other respiratory tract infections, South Korea,142 China138 and UK143  reported even higher percentages 
for ampicillin resistance, due to β-lactamase production, of 47.2%, 31.0% and 37.5%, respectively. 
Such percentages were related with common prescriptions of β-lactams for treatment of H. influenzae 
infections in these countries. Curiously, the UK had been previously reported to possess a higher 
prevalence of β-lactamase producers when compared with other European countries, such as Germany, 
Italy, Poland, Turkey, The Netherlands and Spain, which presented lower prevalences.143,144  
 
 
4.3.2. β-Lactamase-Negative Ampicillin-Resistance (BLNAR) mechanism 
 
In our work, only 2.2% of the isolates were phenotypically identified as BLNAR (Table 3.3). 
These isolates were collected from patients with OM and also presented reduced susceptibility to other 
β-lactam antibiotics, which has been described for BLNAR isolates.140 When compared with the 
previous Portuguese study, that described 7.7% genetically defined BLNAR invasive isolates,55 the 
percentage obtained in the present study was lower, but more similar to percentages reported for other 
countries.138,142,143 Globally, several countries have found low percentages of 4.2%, 5.1%, 6.1% for 
BLNAR isolates in UK,143 China138 and South Korea,142 respectively, among isolates from patients 
with respiratory tract infections. However, a higher percentage of 56.0% BLNAR H. influenzae 
isolates has been described in Spain.141 Likewise, in Japan, before introduction of Hib vaccine, 52.0% 
BLNAR H. influenzae isolates were reported (mostly from patients with respiratory diseases).145 
Similarly, a longitudinal study of meningitis caused by H. influenzae observed an increase in BLNAR 
isolates from 2000 to 2011.146  
A Portuguese study,147 with a majority of respiratory isolates, showed that a selected sample 
characterized as ampicillin non-susceptible isolates (MIC ≥ 1 mg/mL) included 66.7% (94/141) 
BLNAR isolates with ftsI mutations.  
Although BLNAR prevalence among COPD and OM isolates was low, surveillance of this 
resistance mechanism is recommended, since β-lactams are the first line antibiotics commonly used 
for treatment of these diseases in Portugal.39,44  
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4.4. Multilocus Sequence Typing analysis 
 
 MLST is a technique that analyses nucleotide sequences of housekeeping genes. Analysis of 
variations at gene level enables the genetic comparison of different bacterial isolates, which becomes 
useful when studying global epidemiology of disease.24 Different studies have shown that while 
encapsulated H. influenzae isolates are highly clonal and are, therefore, organized in a limited number 
of clusters, NTHi isolates are a genetically diverse population.15,23,55  
In our work, 31 STs were assigned to 41 analysed isolates (16 COPD and 25 OM isolates) 
(Fig. 3.4). Since our isolates were almost all NTHi, these results of great genetic diversity were 
expected, which is in agreement with the 2002–2010 Portuguese study,55 as well as with reports from 
other countries, that also described a highly diverse NTHi population.15,23 Only four STs (155, 389, 
103 and 1218) were shared among COPD and OM isolates, being two of these (STs 155 and 1218) 
closely related to two COPD STs (STs 1281 and 107) (Fig. 3.4). Therefore, we could not establish a 
relationship between determined STs and clinical origin. The most common ST was ST 57, shared 
among three OM isolates (Fig. 3.4) which is in accordance with results from a previous study148 that 
found ST 57 to be the most common ST among OM isolates. These authors even postulated that this 
ST might be representative among OM isolates, contributing to virulence associated with the disease. 
 
 
 
4.5. Virulence genes 
 
 H. influenzae infection starts by adhesion of the bacteria to the mucosa surface of the host. For 
adherence, H. influenzae expresses several surface adhesins, such as PilA, HifA, HMW1A, HMW2A, 
Hia and OMP P5.  
 pilA gene is part of a four-gene cluster, pilABCD, and PilA protein represents the major 
subunit of the type IV pilus in H. influenzae.13,80 In our study, pilA was found in all 38 COPD isolates 
(100%) and in 92.7% (51/55) OM isolates (Table 3.5). Similar results were described by Bakaletz and 
colleagues and Vuong and colleagues, who found a presence of pilA between 91 and 100% of NTHi 
respiratory isolates.13,78  
 hifA belongs to hifABCDE gene cluster and expresses fimbrial HifA, which is the major 
subunit of the fimbriae encoded by the cluster.81 Prevalence of hifA gene was 25.5% in OM isolates 
and 5.3% in COPD isolates (Table 3.5). A study by Geluk and colleagues82 showed a prevalence of 
18% for hifA in NTHi respiratory isolates. Regarding our results, OM isolates presented a similar 
percentage, while COPD isolates presented a lower percentage. 
 hmw1A/2A and hia genes encode mutually exclusive adhesins HMW1A/2A and Hia, 
respectively.77 hmw genes have been shown to undergo phase variation mechanisms related to tandem 
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repeats of 7-bp (ATCTTTC) in the promoters of hmw1A and hmw2A genes. That is, protein expression 
decreases with an increase in the number of repeats.73 In our study, a prevalence of 76.3% was found 
for hmw1A/2A in COPD isolates (Table 3.5). This is in good agreement with different studies that 
described a prevalence of both hmw genes in NTHi respiratory isolates varying from 55 to 100%.78,88  
However, the same was not observed for OM clinical group. In this case, both genes were present in 
25.5% (14/55) of the isolates, while in 7.3% (4/55) of the isolates, only hmw2A was present (Table 3.5 
and 3.6). Ecevit and colleagues,87 also found a different prevalence for the hmw1A/2A genes in NTHi 
isolates collected from the respiratory tract, which was similar to our results. Nevertheless, in that 
study, a higher prevalence was observed for hmw1A gene (51%), when compared with that of hmw2A 
gene (23%).  
 Our study found a higher percentage of hia in OM isolates (41.8%) than in COPD isolates 
(13.2%) (Table 3.5).  Presence of hia gene in OM isolates was more similar to the percentage of 
32.0% , described by Ecevit and colleagues,87 in NTHi respiratory isolates, than to the percentage of  
55.6% described by Cardines and colleagues,89 for invasive NTHi isolates.  
 Since it has been described that hia is present in the absence of the hmw1A/2A genes, this 
relation was assessed (Table 3.6).77 Indeed, presence of hia was only identified in COPD and OM 
isolates lacking both hmw genes. Furthermore, the four OM isolates that only possessed the hmw2A 
gene also lacked hia gene (7.3%). It was further verified that while the majority of COPD isolates 
(76.3%) possessed both hmw genes and lacked hia, the majority of OM isolates (41.8%) lacked both 
hmw genes and possessed hia (Table 3.6). Curiously, when comparing nasopharyngeal and OM 
isolates, Dawid and colleagues73 found that isolates recovered from the ear contained less HMW 
proteins. The authors hypothesized that, since the middle ear is rich in antibodies against HMW1/2, a 
lesser content of these proteins could serve as a survival mechanism for persistence. Even so, it 
appears that this is a controversial topic since results of other studies showed the opposite, with more 
OM isolates possessing hmw1A/2A genes and HMW1/2 expression, than COPD/lower respiratory tract 
isolates.86,87  
Nevertheless, it is interesting to notice that, in the present study, hmw1A/2A genes were more 
prevalent in COPD isolates than in OM isolates and that the presence of hifA and hia, on the other 
hand, was more prevalent in OM isolates than in COPD isolates. Considering the relatively high 
prevalence of hmw1A/2A genes generally described for NTHi isolates, it might be reasonable to 
hypothesize a relationship between type of disease and presence of these virulence genes. These 
differences could be related with adaptations of the bacteria to the different surfaces in each disease 
and with adaptation to the surrounding environment in the respiratory tract. 
 ompP5 gene encodes protein OMP P5 and, like hmw1A/2A, it was also suggested to be 
variably expressed in NTHi. Variability in expression of this protein is related to four variable regions 
in the ompP5 sequences, which result in amino-acid substitutions in loop regions displayed on the 
bacterial surface. Naturally, this variability becomes an advantage for H. influenzae infection, as a 
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selective adaptation mechanism.94 In our study, ompP5 gene was present in 81.6% and 65.5% of 
COPD and OM isolates, respectively (Table 3.5), which is within the range presented by previous 
studies that reported a prevalence for ompP5 from 20%78 to 100%92 in NTHi respiratory isolates. 
 
 
4.6. Biofilms 
 
 In the last two decades, the role of bacterial biofilms has been an important topic of research. 
Biofilms are dynamic assemblies of microorganisms that serve as a bacterial defence mechanism in 
biofilm associated infections and are usually related with persistence of chronic diseases.100,101  
H. influenzae virulence factors such as PilA, HMW1 and HMW2 proteins have been 
suggested to play important roles on different stages of biofilm formation. In an initial stage, these 
proteins are important for adhesion79,86  and, at later stages, these would be secreted and integrated in 
the EPS matrix.106,108  
 
 
4.6.1. Comparison between different classification methods 
 
Biofilms have been recognized as a serious threat to public health over the last two decades. 
These structures constitute a bacterial defence mechanism usually associated with chronic infections, 
which led to a search for new approaches to fight biofilms. However, the need for new efficient 
therapies resulted in the development of different experimental protocols and testing strategies. The 
lack of standardized protocols for biofilm assessment highly hampers a direct comparison between 
results obtained by different laboratories.149 In fact, this same limitation was identified in a study 
conducted by Murphy and Kirkam.113 This problem led Stepanović and colleagues123 to develop a 
classification system that expressed results as numbers, for an easier comparison between different 
studies. This was the classification system used in the present study. 
We intended to establish a comparison between different classification systems and how these 
affected the interpretation of results. Thus, our results were adapted to the classification system 
described in a study conducted by Puig and colleagues.114 This study was elected for presenting an 
experimental protocol similar to that used in the present study. The major difference was in the 
establishment of cut-offs for biofilm production and classification of biofilm producer isolates. With 
the classification system of the study conducted by Puig and colleagues,114 the cut-off OD was higher 
than that obtained with the classification system described by Stepanović and colleagues.123 In our 
study, this translated into a higher number of non-producer isolates and very few producers, either 
after 24h or 48h. Furthermore, after 24h, no COPD isolates were biofilm producers and only two OM 
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and one invasive isolate were producers. These results suggest that the definition of a cut-off 
influences the interpretation of results.  
There is a need to describe a standardized and reproducible classification system for biofilm 
production and for experimental procedures that do not require too much supplies, time and highly 
specialized personnel.149 Otherwise, comparisons of results between different studies, that used 
different protocols and classification systems, are not straightforward and may lead to misleading 
conclusions. 
 
 
4.6.2. Production of biofilm 
 
Several studies have shown the ability of H. influenzae isolates recovered from patients with 
OM and COPD to form biofilms, both in in vitro and in vivo systems.79,105,113-116,118,119 Those studies 
conducted in vitro showed that most H. influenzae isolates were able to form biofilms after 24h 
incubation. These results were not entirely in agreement with ours, since it was verified that only 
14.0% of isolates were able to form a biofilm after 24h incubation (Table 3.7). Furthermore, an overall 
15.0% increase in biofilm production from 24h to 48h incubation (Table 3.7) suggested that isolates 
may require more than 24h to form biofilms. It has been described that efficient attachment is 
influenced by nutrient availability, roughness and hydrophobicity of the surface and surface 
conditioning, which is associated with the medium to which a surface is exposed. Properties of the 
medium, such as specific particles, influence bacterial adhesion to the exposed surface, which will 
vary according to the surrounding environment.98 Thus, the fact that bacterial growth did not increase 
from 24h to 48h and that biofilm production increased, may suggest that biofilm production was a 
slow process and that bacterial cells possibly required this time to adapt to the surrounding 
environment and eventual stress conditions, such as nutrient consumption. Even so, approximately 
71% to 87% of isolates from the three clinical backgrounds that formed a biofilm after 24h were still 
not capable of forming a biofilm after 48h.  
On the other hand, other in vitro studies have also found a low number of biofilm producer 
isolates among both OM and COPD isolates. Mizrahi and colleagues117 found that after 24h 
incubation, 51% of 216 NTHi isolates recovered from patients with AOM (including a control group 
of 43 isolates) were non-biofilm producers, while a study conducted by Martínez-Reséndez and 
colleagues150 described that only 10% of 98 NTHi isolates recovered from patients with lower 
respiratory tract infections (COPD included) were able to produce a biofilm. These studies presented 
results more similar to those obtained in the present study, with most of OM and COPD isolates not 
being able to produce biofilms. The disparity in the results obtained by different studies may be related 
with geographical variations,114 which cannot be excluded, but may mostly be due to different 
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experimental and classification protocols that may affect interpretation of the results, as previously 
explained. 
 
 
4.6.3. Correlation between production of biofilm and an underlying disease 
 
 Few studies have established comparisons between clinical site of isolation and ability of 
NTHi isolates to form biofilms. Puig and colleagues have demonstrated, in two different in vitro 
studies,105,114 that OM isolates were better biofilm producers and formed denser biofilms than COPD 
isolates, which presented similar biofilm production levels to that of healthy carriers. One of these 
studies114 further included invasive isolates that presented the highest levels for biofilm production. 
Our results, obtained after 24h incubation, partially support these findings: OM isolates were, indeed, 
the most capable of producing biofilms after 24h, when compared with COPD isolates. However, 
invasive isolates were the worst biofilm producers, with less biofilm production than OM and COPD 
isolates (Table 3.7 and Fig. 3.5). The results for invasive isolates were the opposite of the expected, 
since these were used as positive controls for biofilm formation. This suggests that genomic analysis 
alone may not have been enough for an inference between presence of the hmw1A/2A genes and 
biofilm production. 
The results of our work could establish a relation between origin of the isolates and biofilm 
production, as follow: from 24h to 48h most COPD isolates tended to increase biofilm production, 
while OM and invasive isolates tended to stabilize, or decrease production. However, statistical 
analysis indicated that the results were not statistically significant and such conclusions could not be 
withdrawn. In addition, it should be considered the small number of isolates that were, in fact, able to 
produce biofilms after 24h incubation (15/107) (Table 3.7) which further limited the establishment of 
a correlation between clinical groups and the ability of isolates to produce biofilms. 
Other authors were also unable to establish a correlation between origin of isolates and 
production of biofilm. Murphy and Kirkam113 conducted an in vitro study with 15 COPD and 15 OM 
isolates and did not highlight significant differences between biofilms produced by NTHi isolates from 
the two different backgrounds. A more recent in vitro study conducted by Obaid and colleagues119 
examined a collection of 60 isolates recovered from oropharyngeal normal floras and patients with 
different diseases – OM, conjunctivitis, lower respiratory tract diseases and cystic fibrosis – and found 
that there was no relation between site of isolation and ability of NTHi isolates to form biofilms. These 
results suggest that a lack of correlation between different clinical groups may not be specific of 
COPD and OM isolates, since the study conducted by Obaid and colleagues,119 was unable to establish 
a correlation between isolates belonging to several respiratory clinical groups. Although these studies 
are more in agreement with the results here presented, it has to be considered the limited number of 
isolates included in both these studies. 
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It should not be excluded the possibility that differences between the results here obtained and 
results from other studies, could be related with different experimental and/or classification systems 
for establishment of biofilm production, as explained before.  
 
 
4.6.4. Virulence factors and biofilm production 
 
Several studies have described a relation between the presence of virulence genes pilA, 
hmw1A and hmw2A with the ability of H. influenzae isolates to produce biofilms.79,86,106,108  
Apparently, a correlation between presence of the selected virulence genes and production of 
biofilm could not be established, with our results. While most COPD and OM biofilm producer 
isolates possessed pilA gene, the majority of isolates identified as non-producers also possessed this 
gene. In addition, while the majority of COPD producer isolates possessed both hmw genes, most OM 
isolates did not. Besides, several non-producer isolates from both clinical groups also possessed these 
genes, which further supported the assumption that no correlation could be established. Curiously, a 
recent study conducted by Cardines and colleagues151 described that isolates with the hmw1A/2A genes 
presented low biofilm production. These assumptions were further supported by our results with 
invasive isolates, all of which possessed hmw1A/2A genes, but very few actually produced a biofilm 
after 24h and 48h.  
It should always be considered that in vitro studies do not reflect what occurs in vivo. 
Furthermore, regarding the three virulence factors, it should be noted that it was only assessed the 
presence of the genes and not the expression levels by transcriptomic analysis. Therefore, the 
production of PilA and HMW1A/2A proteins may significantly differ from isolates grown in vitro, 
than that observed when bacteria grow in the appropriate environment, which may, eventually, 
influence biofilm production. 
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Conclusions and Future Perspectives 
 
 Haemophilus influenzae is an important human-restricted microorganism that, in spite of being 
commonly found in the nasopharynx, it is also able to cause severe invasive diseases, as well as acute 
and chronic infections. NTHi has long been associated with respiratory tract infections, mainly in 
patients with underlying diseases, or with a compromised immune system, which is related to the 
opportunistic behaviour of H. influenzae.  
A sample of 93 H. influenzae isolates collected from patients with COPD and OM, from 2013 
to 2018, was studied. As expected, COPD isolates were recovered from adults (100%), whereas OM 
isolates were mainly recovered from children (98.2%). 
Results from this study showed that NTHi infection was associated with both COPD and OM. 
These results were expected since the presence of NTHi as a commensal of the nasopharynx makes it 
a potential source of infection in both the upper and lower respiratory tract. Therefore, patients with 
COPD and OM usually present NTHi associated infections. 
 The majority of isolates (84.9%) from both clinical groups was susceptible to all antibiotics. 
Ampicillin resistance, mediated by β-lactamase, was observed for 15.8% of COPD isolates and for 
14.5% of OM isolates. It should be noted that one COPD isolate was resistant to ciprofloxacin. This 
was the first H. influenzae ciprofloxacin resistant isolate characterized in the laboratory. 
 MLST, performed for 41 isolates, revealed a high genetic diversity among isolates from both 
clinical backgrounds, with 31 assigned STs. This is also consistent with results obtained from other 
studies that showed a high genetic diversity among NTHi isolates. Although we could not establish a 
general relation between STs and clinical origin, we observed that ST 57 was the most common 
among OM isolates. This result, previously described in literature, could suggest an association of a 
specific genotype with a clinical outcome (in this case, OM). 
  The presence/absence of six virulence genes, assessed for all 93 isolates, revealed a possible 
association with clinical origin. Results showed that pilA and ompP5 genes were present in the 
majority of the isolates. However, hifA and hia genes were observed for less than 50% of COPD and 
OM isolates. Even so, the presence of hifA and hia was higher among OM isolates. In the OM clinical 
group, hmw1A and hmw2A were only present in 25.5% and 32.7% of isolates, respectively, while both 
genes were found together in 76.3% of COPD isolates. We observed a higher prevalence of 
hmw1A/2A genes and a lower prevalence of hifA and hia genes among COPD isolates, while the 
opposite was found for OM isolates. It was further observed that hia gene was present only when hmw 
genes were absent, which is in accordance with the literature. 
 Biofilm production was verified for less than 50% of isolates from all three clinical groups 
(COPD, OM and invasive disease) after 24h and 48h. These results were not in accordance with 
different reports from several authors that showed NTHi as a strong biofilm producer. However, 
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comparisons between different studies have to be carefully evaluated, not only due to possible 
epidemiological factors, but mainly because of a lack in a standardised protocol for biofilm 
assessment. Furthermore, it was not possible to establish a correlation between clinical origin and 
ability of isolates to form biofilms. Similarly, no association was found with the presence of three 
virulence factors: pilA and hmw1A/2A genes, which express adhesins that were previously described as 
key factors for adherence and biofilm formation. 
 It is worth noting that sample size (38 COPD and 55 OM isolates) is a limitation of the present 
study, which hampered the withdrawn of general conclusions. Furthermore, only genomic studies 
were conducted for virulence genes. The performance of a transcriptomic and proteomic analysis of 
these genes could elucidate their role in H. influenzae pathogenesis, in general, as well as in biofilm 
assembly, in particular. 
COPD is one of the leading worldwide diseases. It is prevalent in adults over 40 years old and 
severe patients usually present high rates of morbidity. OM, on the other hand, is the most common 
paediatric disease and it is highly prevalent in the first five years of life. H. influenzae infection 
contributes for an aggravation of the symptoms and persistence of both these diseases.  Given their 
significant impact in society, monitoring and research studies of NTHi in COPD and OM is 
fundamental for the development of better, and more appropriate, prevention and combat strategies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Beatriz da Cunha Batista 
59 
 
References 
 
1. Naushad, S. et al. Phylogenomic and molecular demarcation of the core members of the 
polyphyletic Pasteurellaceae genera Actinobacillus, Haemophilus, and Pasteurella. Int. J. 
Genomics (2015). 
2. Nørskov-Lauritsen, N. Classification, identification, and clinical significance of Haemophilus 
and Aggregatibacter species with host specificity for humans. Clin. Microbiol. Rev. 27, 214–
240 (2014). 
3. http://www.the-icsp.org/taxa-covered-family-pasteurellaceae, consulted on June, 2018 
4. Pfeiffer, R. I. Preliminary communication on the exciting causes of influenza. Br. Med. J. 1, 
128 (1892). 
5. Pittman, M. Variation and type specificity in the bacterial species Haemophilus influenzae. 
471–493 (1931). 
6. Castillo, D. et al. Laboratory Manual for the Diagnosis of Meningitis caused by Neisseria 
meningitidis, Streptococcus pneumoniae and Haemophilus influenzae. Int. J. Epidemiol. 323 
(2011).  
7. https://pubchem.ncbi.nlm.nih.gov/compound/hemin#section=Top, consulted on June, 2018 
8. Reidl, J. et al. NADP and NAD utilization in Haemophilus influenzae. Mol. Microbiol. 35, 
1573–1581 (2000). 
9. Pollak, N., Dölle, C. & Ziegler, M. The power to reduce: pyridine nucleotides – small 
molecules with a multitude of functions. Biochem. J. 402, 205–218 (2007). 
10. Sá-Leão, R. et al. High rates of transmission of and colonization by Streptococcus pneumoniae 
and Haemophilus influenzae within a day care center revealed in a longitudinal study. J. Clin. 
Microbiol. 46, 225–234 (2008). 
11. Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775–
781 (2000). 
12. Erwin, A. L. & Smith, A. L. Nontypeable Haemophilus influenzae: understanding virulence 
and commensal behavior. Trends Microbiol. 15, 355–362 (2007). 
13. Bakaletz, L. O. et al. Demonstration of type IV pilus expression and a twitching phenotype by 
Haemophilus influenzae. Infect. Immun. 73, 1635–1643 (2005). 
14. Sutton, A., Schneerson, R., Kendall-Morris, S. & Robbins, J. B. Differential complement 
resistance mediates virulence of Haemophilus influenzae tybe b. Infect. Immun. 35, 95–104 
(1982). 
15. De Chiara, M. et al. Genome sequencing of disease and carriage isolates of nontypeable 
Haemophilus influenzae identifies discrete population structure. Proc. Natl. Acad. Sci. 111, 
5439–5444 (2014). 
16. King, P. T. & Sharma, R. The lung immune response to nontypeable Haemophilus influenzae 
(Lung Immunity to NTHi). J. Immunol. Res. (2015). 
17. Van Eldere, J., Slack, M. P. E., Ladhani, S. & Cripps, A. W. Non-typeable Haemophilus 
influenzae, an under-recognised pathogen. Lancet Infect. Dis. 14, 1281–1292 (2014). 
18. Kroll, J. S., Zamze, S., Loynds, B. & Moxon, E. R. Common organization of chromosomal loci 
for production of different capsular polysaccharides in Haemophilus influenzae. J. Bacteriol. 
171, 3343–3347 (1989). 
19. Satola, S. W., Schirmer, P. L. & Farley, M. M. Complete sequence of the cap locus of 
Haemophilus influenzae serotype b and nonencapsulated b capsule-negative variants. Infect. 
Immun. 71, 3639–3644 (2003). 
20. Falla, T. J. et al. PCR for capsular typing of Haemophilus influenzae. J. Clin. Microbiol. 32, 
2382–2386 (1994). 
21. Musser, J. M., Kroll, J. S., Moxon, E. R. & Selander, R. K. Clonal population structure of 
encapsulated Haemophilus influenzae. Infect. Immun. 56, 1837–1845 (1988). 
22. Maiden, M. C. J. et al. Multilocus sequence typing: A portable approach to the identification of 
clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. 95, 3140–3145 
(1998). 
23. Meats, E. et al. Characterization of Encapsulated and Noncapsulated Haemophilus influenzae 
and Determination of Phylogenetic Relationships by Multilocus Sequence Typing. J. Clin. 
Haemophilus influenzae in Chronic Obstructive Pulmonary Disease and Otitis Media 
60 
 
Microbiol. 41, 1623–1636 (2003). 
24. Enright, M. C. & Spratt, B. G. Multilocus sequence typing. Trends Microbiol. 7, 482–487 
(1999). 
25. European Centre for Disease Prevention and Control. Annual epidemiological report for 2015 
Haemophilus influenzae. Surveill. Rep. 1–9 (2018). 
26. Execução, D. D. E. & Da, U. E. DECISÃO DE EXECUÇÃO (UE) 2018/945 DA COMISSÃO 
de 22 de junho de 2018 relativa a doenças transmissíveis e problemas de saúde especiais 
conexos que devem ser abrangidos pela vigilância epidemiológica, bem como às definições de 
casos pertinentes. 1–74 (2018). 
27. European Centre for Disease Prevention and Control (ECDC). Vaccine-preventable diseases - 
Invasive bacterial diseases, 2014. Ecdc 33 (2014). 
28. GOLD. GOLD 2017. Glob. Inititiative Chronic Obstr. Lung Dis. 1–139 (2017).  
29. Wong, J., Magun, B. E. & Wood, L. J. Lung inflammation caused by inhaled toxicants: A 
review. Int. J. COPD 11, 1391–1401 (2016). 
30. Berg, K. & Wright, J. L. The Pathology of Chronic Obstructive Pulmonary Disease: Progress 
in the 20th and 21st Centuries. Arch. Pathol. Lab. Med. 140, 1423–1428 (2016). 
31. http://www.who.int/mediacentre/factsheets/fs315/en/, consulted on February, 2018 
32. http://www.who.int/respiratory/copd/burden/en/, consulted on February, 2018 
33. Celli, B. R. et al. Standards for the diagnosis and treatment of patients with COPD: A summary 
of the ATS/ERS position paper. Eur. Respir. J. 23, 932–946 (2004). 
34. Alikhan, M. M. & Lee, F. E.-H. Understanding nontypeable Haemophilus influenzae and 
chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 20, 159–164 (2014). 
35. Domenech, A. et al. Infectious etiology of acute exacerbations in severe COPD patients. J. 
Infect. 67, 516–523 (2013). 
36. Patel, I. S. et al. Relationship between bacterial colonisation and the frequency, character, and 
severity of COPD exacerbations. Thorax 57, 759–764 (2002). 
37. Sethi, S., Wrona, C., Grant, B. J. B. & Murphy, T. F. Strain-specific Immune Response to 
Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care 
Med. 169, 448–453 (2004). 
38. Chick, D. A. Chronic obstructive pulmonary disease: Role of Bacteria and Updated Guide to 
Antibacterial Selection in the Older Patient. Univ. Michigan Heal. Syst. 137, 251–269 (2012). 
39. Direção-Geral de Saúde. Diagnóstico e Tratamento da Doença Pulmonar Obstrutiva Crónica. 
Norma da Direção-Geral da Saúde 1, 1–15 (2013). 
40. Murphy, T. F. et al. Nontypeable Haemophilus influenzae as a Pathogen in Children. Pediatr. 
Infect. Dis. J. 28, 43–48 (2009). 
41. Qureishi, A., Lee, Y., Belfield, K., Birchall, J. P. & Daniel, M. Update on otitis media - 
Prevention and treatment. Infect. Drug Resist. 7, 15–24 (2014). 
42. van Zon, A., van der Heijden, G. J., van Dongen, T. M. A., Burton, M. J. & Schilder, A. G. M. 
Antibiotics for otitis media with effusion in children. Cochrane Collab. CD009163 (2012).  
43. Monasta, L. et al. Burden of disease caused by otitis media: Systematic review and global 
estimates. PLoS One 7, (2012). 
44. Fernanda, R., Brett, A., Januário, G., Marques, J. G. & Gonçalves, M. Norma para o 
Diagnóstico e Tratamento da Otite Média Aguda na Idade Pediátrica. Direção Geral de Saúde 
1–13 (2014). 
45. Prymula, R. & Schuerman, L. 10-Valent pneumococcal nontypeable Haemophilus influenzae 
PD conjugate vaccine: SynflorixTM. Expert Rev. Vaccines 8, 1479–1500 (2009). 
46. Prymula, R. et al. Pneumococcal capsular polysaccharides conjugated to protein D for 
prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable 
Haemophilus influenzae: a randomized double-blind efficacy study. Lancet 367, (2006). 
47. Agrawal, A. & Murphy, T. F. Haemophilus influenzae infections in the H. influenzae type b 
conjugate vaccine era. J. Clin. Microbiol. 49, 3728–3732 (2011). 
48. Wang, S., Tafalla, M., Hanssens, L. & Dolhain, J. A review of Haemophilus influenzae disease 
in Europe from 2000–2014: challenges, successes and the contribution of hexavalent 
combination vaccines. Expert Rev. Vaccines 16, 1095–1105 (2017). 
49. Anderson, E. C. et al. Epidemiology of invasive Haemophilus influenzae infections in England 
 Beatriz da Cunha Batista 
61 
 
and Wales in the pre-vaccination era (1990–2). Epidemiol. Infect. 115, 89–100 (1995). 
50. http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-
immunization/vaccine-preventable-diseases/haemophilus-influenzae-type-b-hib, consulted on 
September, 2018 
51. Whittaker, R. et al. Epidemiology of invasive Haemophilus influenzae disease, Europe, 2007–
2014. Emerg. Infect. Dis. 23, 396–404 (2017). 
52. Murphy, T. F. Vaccines for nontypeable Haemophilus influenzae: The future is now. Clin. 
Vaccine Immunol. 22, 459–466 (2015). 
53. Ikeda, M. et al. Nontypeable Haemophilus influenzae exploits the interaction between protein-
E and vitronectin for the adherence and invasion to bronchial epithelial cells. BMC Microbiol. 
15, 1–11 (2015). 
54. Bajanca, P. & Caniça, M. Emergence of Nonencapsulated and Encapsulated Non-b-Type 
Invasive Haemophilus influenzae Isolates in Portugal (1989-2001). J. Clin. Microbiol. 42, 807–
810 (2004). 
55. Bajanca-Lavado, M. P. et al. Characteristics of Haemophilus influenzae invasive isolates from 
Portugal following routine childhood vaccination against H. influenzae serotype b (2002-2010). 
Eur. J. Clin. Microbiol. Infect. Dis. 33, 603–610 (2014). 
56. Cunha, F. & Lavado, P. Doença Invasiva por Haemophilus influenzae na Criança : Estudo 
Multicêntrico Nacional 2010-2014. 21–29 (2016). 
57. Calado, R. et al. Complicated Meningitis caused by a rare serotype of Haemophilus influenzae 
in Portugal. Diagn. Microbiol. Infect. Dis. 69, 111–113 (2011). 
58. Etebu, E. & Arikekpar, I. Antibiotics: Classification and mechanisms of action with emphasis 
on molecular perspectives. Ijambr 4, 90–101 (2016). 
59. G. Kapoor, S. Saigal, A. E. Action and resistance mechanisms of antibiotics: A guide for 
clinicians. J. Anaesthesiol. Clin. Pharmacol. 33, 300–305 (2017). 
60. Needham, C. A. Haemophilus influenzae: antibiotic susceptibility. Clin.Microbiol.Rev. 1, 218–
227 (1988). 
61. Committee, T. E., Testing, A. S., Changes, N. & Pseudomonas, E. European Committee on 
Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone 
diameters European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for 
interpretation of MICs and zone diameters. 3–7 (2018). 
62. Tristram, S., Jacobs, M. R. & Appelbaum, P. C. Antimicrobial resistance in Haemophilus 
influenzae. Clin. Microbiol. Rev. 20, 368–389 (2007). 
63. http://tmedweb.tulane.edu/pharmwiki/doku.php/betalactam_pharm, consulted on July, 2018 
64. Alekshun, M. N. & Levy, S. B. Molecular Mechanisms of Antibacterial Multidrug Resistance. 
Cell 128, 1037–1050 (2007). 
65. Sakulchit, T. & Goldman, R. D. Antibiotic therapy for children with acute otitis media. Can. 
Fam. Physician 63, 685–687 (2017). 
66. Worthington, R. J. & Melander, C. Overcoming Resistance to β-Lactam Antibiotics. J Org 
Chem. 78, 4207–4213 (2013). 
67. Reading, C. et al. Clavulanic acid: a β-Lactamase-inhibiting β-lactam from Streptomyces 
clavuligerus. Antimicrob. Agents Chemother. 11, 852–857 (1977). 
68. Ubukata, K. et al. Association of Amino Acid Substitutions in Penicillin-Binding Protein 3 
with β-Lactam Resistance in β-Lactamase-Negative Ampicillin-Resistant Haemophilus 
Association of Amino Acid Substitutions in Penicillin-Binding Protein 3 with β-Lactam 
Resistance i. 45, 1693–1699 (2001). 
69. Matic, V., Bozdogan, B., Jacobs, M. R., Ubukata, K. & Appelbaum, P. C. Contribution of β-
lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in β-
lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae. J. Antimicrob. 
Chemother. 52, 1018–1021 (2003). 
70. Duell, B. L., Su, Y. C. & Riesbeck, K. Host–pathogen interactions of nontypeable 
Haemophilus influenzae: from commensal to pathogen. FEBS Lett. 590, 3840–3853 (2016). 
71. Rao, V. K., Krasan, G. P., Hendrixson, D. R., Dawid, S. & St. Geme, J. W. Molecular 
determinants of the pathogenesis of disease due to non-typable Haemophilus influenzae. FEMS 
Microbiol. Rev. 23, 99–129 (1999). 
Haemophilus influenzae in Chronic Obstructive Pulmonary Disease and Otitis Media 
62 
 
72. Male, C. J. Immunoglobulin Al Protease Production by Haemophilus influenzae and 
Streptococcus pneumoniae. 26, 254–261 (1979). 
73. Dawid, S., Barenkamp, S. J. & St Geme, J. W. Variation in expression of the Haemophilus 
influenzae HMW adhesins: a prokaryotic system reminiscent of eukaryotes. Proc. Natl. Acad. 
Sci. U. S. A. 96, 1077–82 (1999). 
74. Kubiet, M., Ramphal, R., Weber, A. & Smith, A. Pilus-mediated adherence of Haemophilus 
influenzae to human respiratory mucins. Infect. Immun. 68, 3362–3367 (2000). 
75. Rodriguez, C. A. et al. Prevalence and distribution of adhesins in invasive non-type b 
encapsulated Haemophilus influenzae. Infect. Immun. 71, 1635–1642 (2003). 
76. St Geme, J. W., Falkow, S. & Barenkamp, S. J. High-molecular-weight proteins of nontypable 
Haemophilus influenzae mediate attachment to human epithelial cells. Proc. Natl. Acad. Sci. U. 
S. A. 90, 2875–2879 (1993). 
77. St Geme, J. W., Kumar, V. V., Cutter, D. & Barenkamp, S. J. Prevalence and distribution of 
the hmw and hia genes and the HMW and Hia adhesins among genetically diverse strains of 
nontypeable Haemophilus influenzae. Infect. Immun. 66, 364–368 (1998). 
78. Vuong, J. et al. Absence of high molecular weight proteins 1 and/or 2 is associated with 
decreased adherence among non-typeable Haemophilus influenzae clinical isolates. 1649–1656 
(2013).  
79. Jurcisek, J. A. et al. The PilA protein of non-typeable Haemophilus influenzae plays a role in 
biofilm formation, adherence to epithelial cells and colonization of the mammalian upper 
respiratory tract. Mol. Microbiol. 65, 1288–1299 (2007). 
80. Carruthers, M. D. et al. Biological roles of nontypeable Haemophilus influenzae type IV pilus 
proteins encoded by the pil and com operons. J. Bacteriol. 194, 1927–1933 (2012). 
81. Van Ham, S. M., Van Alphen, L., Mooi, F. R. & Van Putten, J. P. M. Contribution of the major 
and minor subunits to fimbria-mediated adherence of Haemophilus influenzae to human 
epithelial cells and erythrocytes. Infect. Immun. 63, 4883–4889 (1995). 
82. Geluk, F., Eijk, P. P., Van Ham, S. M., Jansen, H. M. & Van Alphen, L. The fimbria gene 
cluster of nonencapsulated Haemophilus influenzae. Infect. Immun. 66, 406–417 (1998). 
83. Barenkamp, S. J. & Leininger, E. Cloning, expression, and DNA sequence analysis of genes 
encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed 
proteins related to filamentous hemagglutinin of Bordetella pertussis. Infect Immun 60, 1302–
1313 (1992). 
84. Atack, J. M. et al. The HMW2 adhesin of non-typeable Haemophilus influenzae is a human-
adapted lectin that mediates high-affinity binding to 2–6 linked N-acetylneuraminic acid 
glycans. Biochem. Biophys. Res. Commun. 503, 1103–1107 (2018). 
85. St. Geme, J. W. The HMW1 adhesin of nontypeable Haemophilus influenzae recognizes 
sialylated glycoprotein receptors on cultured human epithelial cells. Infect. Immun. 62, 3881–
3889 (1994). 
86. van Schilfgaarde, M. et al. Characterization of adherence of nontypeable Haemophilus 
influenzae to human epithelial cells. Infect Immun 68, 4658–4665 (2000). 
87. Ecevit, I. Z. et al. Prevalence of the hifBC, hmw1A, hmw2A, hmwC, and hia genes in 
Haemophilus influenzae Isolates. Society 42, 3065–3072 (2004). 
88. Buscher, A. Z., Burmeister, K. & Barenkamp, S. J. Evolutionary and Functional Relationships 
among the Nontypeable Haemophilus influenzae HMW Family of Adhesins. Society 186, 
4209–4217 (2004). 
89. Cardines, R., Giufre, M., Mastrantonio, P., degli Atti, M. L. C. & Cerquetti, M. Nontypeable 
Haemophilus influenzae Meningitis in Children: Phenotypic and Genotypic Characterization of 
Isolates. Pediatr. Infect. Dis. J. 26, 577–582 (2007). 
90. Barenkamp, S. J. & St. Geme, J. W. Identification of a second family of high-molecular-weight 
adhesion proteins expressed by non-typable Haemophilus influenzae. Mol. Microbiol. 19, 
1215–1223 (1996). 
91. Erwin, A. L. et al. Analysis of genetic relatedness of Haemophilus influenzae isolates by 
multilocus sequence typing. J. Bacteriol. 190, 1473–1483 (2008). 
92. Martí-Lliteras, P. et al. Nontypable Haemophilus influenzae displays a prevalent surface 
structure molecular pattern in clinical isolates. PLoS One 6, (2011). 
 Beatriz da Cunha Batista 
63 
 
93. Hill, D. J. et al. The variable P5 proteins of typeable and non-typeable Haemophilus influenzae 
target human CAECAM1. Mol Microbiol 39, 850–862 (2001). 
94. Duim, B. et al. Molecular variation in the major outer membrane protein P5 gene of 
nonencapsulated Haemophilus influenzae during chronic infections. Infec Immun 65, 1351–
1356 (1997). 
95. Gray-Owen, S. D., Loosmore, S. & Schryvers, A. B. Identification and characterization of 
genes encoding the human transferrin-binding proteins from Haemophilus influenzae. Infect 
Immun 63, 1201–1210 (1995). 
96. Seale, T. W. et al. Complex role of hemoglobin and hemoglobin-haptoglobin binding proteins 
in Haemophilus influenzae virulence in the infant rat model of invasive infection. Infect. 
Immun. 74, 6213–6225 (2006). 
97. Fink, D. L., Green, B. A. & St. Geme, J. W. The Haemophilus influenzae Hap autotransporter 
binds to fibronectin, laminin, and collagen IV. Infect. Immun. 70, 4902–4907 (2002). 
98. Donlan, R. M. Biofilms: Microbial life on surfaces. Emerg. Infect. Dis. 8, 881–890 (2002). 
99. Kostakioti, M., Hadjifrangiskou, M. & Hultgren, S. J. Bacterial biofilms: Development, 
dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harb. 
Perspect. Med. 3, 1–23 (2013). 
100. Hyun Koo, Raymond N Allan, Robert P Howlin, L. H.-S. and P. S. Targeting microbial 
biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol. 15, 740–755 
(2017). 
101. Jamal, M., Tasneem, U., Hussain, T. & Andleeb,  and S. Bacterial Biofilm: Its Composition, 
Formation and Role in Human Infections. Res. Rev. J. Microbiol. Biotechnol. 4, 1–14 (2015). 
102. Macià, M. D., Rojo-Molinero, E. & Oliver, A. Antimicrobial susceptibility testing in biofilm-
growing bacteria. Clin. Microbiol. Infect. 20, 981–990 (2014). 
103. Murphy, T. F., Brauer, A. L., Schiffmacher, A. T. & Sethi, S. Persistent Colonization by 
Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care 
Med. 170, 266–272 (2004). 
104. Swords, W. E. Nontypeable Haemophilus influenzae biofilms: role in chronic airway 
infections. Front. Cell. Infect. Microbiol. 2, 1–5 (2012). 
105. Puig, C. et al. Incorporation of phosphorylcholine into the lipooligosaccharide of nontypeable 
Haemophilus influenzae does not correlate with the level of biofilm formation in vitro. Infect. 
Immun. 82, 1591–1599 (2014). 
106. Jurcisek, J. A. & Bakaletz, L. O. Biofilms formed by nontypeable Haemophilus influenzae in 
vivo contain both double-stranded DNA and type IV pilin protein. J. Bacteriol. 189, 3868–
3875 (2007). 
107. Mokrzan, E. M., Ward, M. O. & Bakaletz, L. O. Type IV pilus expression is upregulated in 
nontypeable Haemophilus influenzae biofilms formed at the temperature of the human 
nasopharynx. J. Bacteriol. 198, JB.01022-15 (2016). 
108. Webster, P. et al. Distribution of bacterial proteins in biofilms formed by non-typeable 
Haemophilus influenzae. J. Histochem. Cytochem. 54, 829–842 (2006). 
109. Takahata, M., Sugiura, Y., Shinmura, Y., Fukuda, Y. & Nomura, N. Bactericidal activity of 
garenoxacin against in vitro biofilm formed by nontypeable Haemophilus influenzae. J. Infect. 
Chemother. 19, 441–446 (2013). 
110. Wu, S. et al. Beta-lactam antibiotics stimulate biofilm formation in non-typeable Haemophilus 
influenzae by up-regulating carbohydrate metabolism. PLoS One 9, (2014). 
111. Armbruster, C. E., Hong, W. & Pang, B. Indirect Pathogenicity of Haemophilus influenzae and 
Moraxella catarrhalis in Polymicrobial Otitis Media Occurs via Interspecies Quorum 
Signaling. 1, 1–9 (2010). 
112. Tikhomirova, A. & Kidd, S. P. Haemophilus influenzae and Streptococcus pneumoniae: Living 
together in a biofilm. Pathog. Dis. 69, 114–126 (2013). 
113. Murphy, T. F. & Kirkham, C. Biofilm formation by nontypeable Haemophilus influenzae: 
Strain variability, outer membrane antigen expression and role of pili. BMC Microbiol. 2, 1–8 
(2002). 
114. Puig, C. et al. Increased biofilm formation by nontypeable Haemophilus influenzae isolates 
from patients with invasive disease or otitis media versus strains recovered from cases of 
Haemophilus influenzae in Chronic Obstructive Pulmonary Disease and Otitis Media 
64 
 
respiratory infections. Appl. Environ. Microbiol. 80, 7088–7095 (2014). 
115. García-Cobos, S. et al. Frequent carriage of resistance mechanisms to β-lactams and biofilm 
formation in Haemophilus influenzae causing treatment failure and recurrent otitis media in 
young children. J. Antimicrob. Chemother. 69, 2394–2399 (2014). 
116. Yano, H. et al. Improvement rate of acute otitis media caused by Haemophilus influenzae at 1 
week is significantly associated with time to recovery. J. Clin. Microbiol. 51, 3542–3546 
(2013). 
117. Mizrahi, A. et al. Non typable-Haemophilus influenzae biofilm formation and acute otitis 
media. BMC Infect. Dis. 14, 1–10 (2014). 
118. Dragoi, L. et al. Modulation of biofilm of strains isolated from patients with chronic 
obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, 
amoxicillin/clavulanic acid and ceftriaxone. 24, 1027–1035 (2011). 
119. Obaid, N. A., Jacobson, G. A. & Tristram, S. Relationship between clinical site of isolation and 
ability to form biofilms in vitro in nontypeable Haemophilus influenzae. Can. J. Microbiol. 61, 
243–245 (2015). 
120. O’Callaghan, C. H., Morris, A., Kirby, S. M. & Shingler, A. H. Novel method for detection of 
beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents 
Chemother. 1, 283–288 (1972). 
121. Reference, Q. ExoSAP-IT TM PCR Product Cleanup Brief Protocol. (2017). 
122. Stepanović, S., Vuković, D., Dakić, I., Savić, B. & Švabić-Vlahović, M. A modified microtiter-
plate test for quantification of staphylococcal biofilm formation. J. Microbiol. Methods 40, 
175–179 (2000). 
123. Stepanovic, S. et al. Quantification of Biofilm in Microtiter Plates: Overview of Testing 
Conditions and Practical Recommendations for Assessment of Biofilm Production by 
Staphylococci. Apmis 115, 891–899 (2007). 
124. Rules, E. European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for 
interpretation of MICs and zone diameters European Committee on Antimicrobial 
Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. (2017). 
125. Soeters, H. M. et al. Current Epidemiology and Trends in Invasive Haemophilus influenzae 
Disease—United States, 2009–2015. Oxford University Press for the Infectious Diseases 
Society of America (2015). 
126. Watt, J. P. et al. Burden of disease caused by Haemophilus influenzae type b in children 
younger than 5 years: global estimates. Lancet 374, 903–911 (2009). 
127. Ulanova, M. & Tsang, R. S. W. Haemophilus influenzae serotype a as a cause of serious 
invasive infections. Lancet Infect. Dis. 14, 70–82 (2014). 
128. Langereis, J. D. & De Jonge, M. I. Invasive disease caused by nontypeable Haemophilus 
influenzae. Emerg. Infect. Dis. 21, 1711–1718 (2015). 
129. Blanco, I. et al. Geographical distribution of COPD prevalence in Europe, estimated by an 
inverse distance weighting interpolation technique. Int. J. COPD 13, 57–67 (2018). 
130. Landis, S. H. et al. Continuing to confront COPD international patient survey: Methods, COPD 
prevalence, and disease burden in 2012-2013. Int. J. COPD 9, 597–607 (2014). 
131. Foo, J. et al. Continuing to confront COPD international patient survey: Economic impact of 
COPD in 12 countries. PLoS One 11, 1–15 (2016). 
132. Chidozie, A. H., Uchegbu, U., Johnkennedy, N., Uloneme, G. C. & Catherine, A. Effects of 
Gender and Seasonal Variation on the Prevalence of Otitis Media Among Young Children in 
Owerri , Imo State Nigeria. 6, 4465–4467 (2015). 
133. Zhang, Y. et al. Risk factors for chronic and recurrent otitis media-A meta-analysis. PLoS One 
9, (2014). 
134. Sriram, K. B., Cox, A. J., Clancy, R. L., Slack, M. P. E. & Cripps, A. W. Nontypeable 
Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians. 
Crit. Rev. Microbiol. 7828, 1–18 (2017). 
135. Sierra, A. et al. Non-typeable Haemophilus influenzae and Streptococcus pneumoniae as 
primary causes of acute otitis media in colombian children: A prospective study. BMC Infect. 
Dis. 11, 4 (2011). 
136. Lugade, A. A. & Thanavala, Y. Role of Nontypeable Haemophilus influenzae in Otitis Media 
 Beatriz da Cunha Batista 
65 
 
and Chronic Obstructive Pulmonary Disease. Adv. Oto-Rhino-Laryngology - Karger Publ. 72, 
170–175 (2011). 
137. Tsang, R. S. W. et al. Antibiotic susceptibility and molecular analysis of invasive Haemophilus 
influenzae in Canada, 2007 to 2014. J. Antimicrob. Chemother. 72, 1314–1319 (2017). 
138. Zhang, Y. et al. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus 
influenzae and Moraxella catarrhalis isolated from community-acquired respiratory tract 
infections in China: Results from the CARTIPS Antimicrobial Surveillance Program. J. Glob. 
Antimicrob. Resist. 5, 36–41 (2016). 
139. Barriere, S. L. & Hindler, J. A. Ciprofloxacin-resistant Haemophilus influenzae infection in a 
patient with chronic lung disease. Ann. Pharmacother. 27, 309–10 (1993). 
140. Puig, C. et al. Molecular characterization of fluoroquinolone resistance in nontypeable 
Haemophilus influenzae clinical isolates. Antimicrob. Agents Chemother. 59, 461–466 (2015). 
141. García-Cobos, S. et al. Ampicillin-resistant non-β-lactamase-producing Haemophilus 
influenzae in Spain: Recent emergence of clonal isolates with increased resistance to 
cefotaxime and cefixime. Antimicrob. Agents Chemother. 51, 2564–2573 (2007). 
142. Bae, S. et al. Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in 
Korea: Results of a nationwide acute respiratory infections surveillance. Antimicrob. Agents 
Chemother. 54, 65–71 (2010). 
143. Maddi, S. et al. Ampicillin resistance in Haemophilus influenzae from COPD patients in the 
UK. Int. J. COPD 12, 1507–1518 (2017). 
144. Morrissey, I. et al. Non-susceptibility trends among Haemophilus influenzae and Moraxella 
catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-
2007. J. Antimicrob. Chemother. 62, 97–103 (2008). 
145. Sanbongi, Y. et al. Molecular evolution of β-lactam-resistant Haemophilus influenzae: 9-Year 
surveillance of penicillin-binding protein 3 mutations in isolates from Japan. Antimicrob. 
Agents Chemother. 50, 2487–2492 (2006). 
146. Ubukata, K., Chiba, N., Morozumi, M., Iwata, S. & Sunakawa, K. Longitudinal surveillance of 
Haemophilus influenzae isolates from pediatric patients with meningitis throughout Japan, 
2000-2011. J. Infect. Chemother. 19, 34–41 (2013). 
147. Barbosa, A. R., Giufrè, M., Cerquetti, M. & Bajanca-Lavado, M. P. Polymorphism in ftsI gene 
and β-lactam susceptibility in Portuguese Haemophilus influenzae strains: clonal dissemination 
of β-lactamase-positive isolates with decreased susceptibility to amoxicillin/clavulanic acid. J. 
Antimicrob. Chemother. 66, 788–796 (2011). 
148. LaCross, N. C., Marrs, C. F. & Gilsdorf, J. R. Population structure in nontypeable 
Haemophilus influenzae. Infect. Genet. Evol. 14, 125–36 (2013). 
149. Malone, M. et al. Approaches to biofilm-associated infections: the need for standardized and 
relevant biofilm methods for clinical applications. Expert Rev. Anti. Infect. Ther. 15, 147–156 
(2017). 
150. Martínez-Reséndez, M. F. et al. Non-typeable Haemophilus influenzae biofilm production and 
severity in lower respiratory tract infections in a tertiary hospital in Mexico. J. Med. Microbiol. 
65, 1385–1391 (2016). 
151. Cardines, R. et al. Haemophilus influenzae in children with cystic fibrosis: Antimicrobial 
susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int. J. 
Med. Microbiol. 302, 45–52 (2012). 
 
 
 
 
 
 
 
 
Haemophilus influenzae in Chronic Obstructive Pulmonary Disease and Otitis Media 
66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(page intentionally left blank) 
Beatriz da Cunha Batista 
67 
 
 
5. Appendix 
Appendix 5.1. 
 
Table 5.1 | COPD isolates data and characterization.  
      
Biofilm 
Production* 
H. influenzae ID Isolation Date Gender β-Lactamase Capsule pilA ompP5 hmw1A hmw2A hifA hia 24h 48h 
12885 
2013 
Male Negative 
Non-
encapsulated 
Present Present Absent Absent Absent Absent - - 
12886 Male Negative Present Present Absent Absent Absent Present - - 
12963 Female Negative Present Present Present Present Absent Absent - - 
12986 Male Negative Present Present Present Present Absent Absent - 1 
13007 Male Negative Present Present Present Present Absent Absent - 1 
13123 
2014 
Male Negative Non-
encapsulated 
Present Present Absent Absent Present Present - 1 
13156 Male Negative Present Present Present Present Absent Absent - 1 
13303 Male Negative Present Present Present Present Absent Absent - - 
13354 
2015 
Male Negative 
Non-
encapsulated 
Present Present Present Present Absent Absent 1 1 
13360 Female Negative Present Present Present Present Absent Absent - 1 
13390 Male Negative Present Present Present Present Absent Absent - 1 
13391 Male Negative Present Present Present Present Absent Absent - 1 
13394 Male Positive Present Present Present Present Absent Absent - 1 
13395 Male Positive Present Present Present Present Absent Absent - 1 
13421 Female Negative Present Absent Present Present Absent Absent - 1 
13424 Male Negative Present Absent Present Present Absent Absent - - 
13449 Male Negative Present Absent Absent Absent Absent Absent - - 
13463 Male Negative Present Absent Absent Absent Absent Absent - - 
13491 Female Negative Present Present Present Present Absent Absent 1 1 
*Regarding biofilm production, numbers indicate the ODisolate/ODcut-off ratio. 
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Table 5.1 | COPD isolates data and characterization.  
      
Biofilm 
Production* 
H. influenzae ID Isolation Date Gender β-Lactamase Capsule pilA ompP5 hmw1A hmw2A hifA hia 24h 48h 
13515 
2016 
Male Negative 
Non-
encapsulated 
Present Absent Absent Absent Absent Present - 1 
13556 Male Negative Present Present Present Present Absent Absent - 1 
13558 Male Negative Present Present Present Present Absent Absent 1 2 
13559 Male Negative Present Present Present Present Absent Absent - 1 
13593 Male Negative Present Absent Absent Absent Absent Present 2 3 
13615 Male Negative Present Absent Present Present Absent Absent 1 2 
13638 Male Negative Encapsulated (f) Present Present Absent Absent Present Absent - 1 
13645 
2017 
Male Positive 
Non-
encapsulated 
Present Present Present Present Absent Absent - 2 
13647 Male Negative Present Present Present Present Absent Absent - 2 
13655 Male Negative Present Present Present Present Absent Absent - 1 
13696 Male Positive Present Present Present Present Absent Absent 1 3 
13703 Male Negative Present Present Present Present Absent Absent 1 2 
13716 Female Negative Present Present Present Present Absent Absent - 2 
13727 Male Negative Present Present Present Present Absent Absent 1 1 
13728 Male Positive Present Present Present Present Absent Absent 2 3 
13758 Male Negative Present Present Present Present Absent Absent - 2 
13776 Male Negative Present Present Absent Absent Absent Present 1 2 
13777 Male Positive Present Present Present Present Absent Absent 1 2 
13791 2018 Female Negative Non-encapsulated Present Present Present Present Absent Absent 2 2 
*Regarding biofilm production, numbers indicate the ODisolate/ODcut-off ratio.  
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Appendix 5.2. 
 
Table 5.2 | OM isolates data and characterization.  
     
Biofilm 
Production* 
H. influenzae ID Isolation Date Gender β-Lactamase Capsule pilA ompP5 hmw1A hmw2A hifA hia 24h 48h 
12579 
2013 
Male Negative 
Non-
Encapsulated 
Present Absent Absent Absent Absent Absent 1 1 
12580 Female Negative Present Absent Present Present Absent Absent - 1 
12595 Female Positive Present Present Absent Present Absent Absent - 1 
12608 Female Negative Present Absent Present Present Absent Absent - 1 
12635 Female Negative Present Present Absent Absent Present Absent 1 2 
12693 Male Negative Present Present Absent Absent Absent Present 1 2 
12717 Male Negative Present Absent Present Present Absent Absent 1 2 
12719 Female Negative Present Present Absent Absent Present Absent - - 
12733 Male Positive Present Absent Present Present Absent Absent - 1 
12734 Female Negative Present Present Absent Absent Present Absent 2 2 
12735 Male Negative Present Absent Present Present Absent Absent - 1 
12880 Male Positive Present Absent Absent Absent Present Absent 1 1 
12906 Male Negative Present Present Absent Absent Absent Present 2 2 
12931 Male Negative Present Present Absent Absent Absent Present 2 2 
12860 
2014 
Female Negative 
Non-
Encapsulated 
Present Present Present Present Absent Absent - 1 
12925 Male Negative Present Present Absent Absent Absent Absent 1 2 
12939 Female Positive Present Present Present Present Absent Absent - 2 
12957 Male Negative Present Present Absent Absent Absent Present 1 1 
12968 Female Negative Present Present Present Present Absent Absent - 1 
13002 Female Positive Present Present Absent Present Absent Absent - 1 
13030 Male Positive Present Present Present Present Absent Absent - 1 
13078 Male Negative Present Present Absent Absent Present Present 1 2 
13083 Female Negative Absent Absent Absent Absent Present Absent 2 2 
13102 Female Negative Present Present Absent Absent Absent Present 2 2 
*Regarding biofilm production, numbers indicate the ODisolate/ODcut-off ratio. 
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Biofilm 
Production* 
H. influenzae ID Isolation Date Gender β-Lactamase Capsule pilA ompP5 hmw1A hmw2A hifA hia 24h 48h 
13164 
2014 
Male Negative 
Non-
Encapsulated 
Present Present Absent Absent Present Present - 1 
13165 Male Negative Present Absent Absent Present Absent Absent - 1 
13166 Male Negative Present Present Present Present Absent Absent - 1 
13167 Male Negative Present Present Absent Absent Absent Absent - 1 
13223 Male Negative Present Present Absent Absent Absent Absent - 1 
13224 Female Negative Present Present Absent Absent Present Present 3 3 
13225 Male Negative Present Present Absent Absent Present Present - - 
13309 Female Negative Present Present Absent Absent Present Absent - 1 
13283 
2015 
Female Negative 
Non-
Encapsulated 
Present Absent Absent Absent Absent Present - - 
13340 Female Negative Absent Present Absent Absent Present Absent - 1 
13352 Male Negative Present Absent Absent Absent Absent Absent - - 
13425 Male Negative Present Absent Present Present Absent Absent - 1 
13450 Female Negative Present Present Absent Absent Absent Present - - 
13623 
2017 
Male Negative 
Non-
Encapsulated 
Present Present Present Present Absent Absent - 1 
13628 Male Negative Present Present Absent Absent Absent Present 1 1 
13632 Female Negative Present Present Absent Absent Absent Present - - 
13660 Female Negative Present Absent Present Present Absent Absent - - 
13673 Female Negative Present Present Absent Absent Absent Present - - 
13674 Male Positive Present Present Absent Present Absent Absent - - 
13686 Female Negative Present Absent Present Present Absent Absent - - 
13692 Female Negative Present Absent Absent Absent Absent Present - - 
13693 Female Negative Present Absent Absent Absent Absent Present - 1 
13739 Male Negative Present Absent Absent Absent Absent Present 1 1 
13740 Male Negative Present Absent Absent Absent Present Absent 1 1 
13741 Male Positive Present Present Absent Absent Present Present 1 1 
13742 Female Negative Present Absent Absent Absent Absent Present - 1 
13744 Female Negative Absent Present Absent Absent Absent Present 1 1 
13770 Male Negative Absent Present Absent Absent Absent Present 2 2 
*Regarding biofilm production, numbers indicate the ODisolate/ODcut-off ratio. 
Table 5.2 | OM isolates data and characterization.  
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Table 5.2 | OM isolates data and characterization. 
     
Biofilm 
Production* 
H. influenzae ID Isolation Date Gender β-Lactamase Capsule pilA ompP5 hmw1A hmw2A hifA hia 24h 48h 
13787 2018 Female Negative 
Non-
Encapsulated 
Present Present Absent Absent Absent Present 2 2 
13795 2017 Male Negative Present Present Absent Absent Absent Absent 2 1 
13801 2018 Female Negative Present Present Absent Absent Present Present 2 2 
*Regarding biofilm production, numbers indicate the ODisolate/ODcut-off ratio. 
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Appendix 5.3.  
 
Table 5.3 | Primers used for capsular typing.20 
Primer name Sequence (5'- 3') Use Length of fragment (bp) 
Hi1  CGTTTGTATGATGTTGATCCAGAC  
Capsule amplification (bexA gene) 343 
Hi2  TGTCCATGTCTITCAAAATGATG 
Hia1 CTACTCATTGCAGCATTTGC 
Serotype a characterization 250 
Hia2 GAATATGACCTGATCTTCTG 
Hib1  GCGAAAGTGAACTCTTATCTCTC 
Serotype b characterization 480 
Hib2  GCTTACGCTTCTATCTCGGTGAA 
Hic1  TCTGTGTAGATGATGGTTCA  
Serotype c characterization 250 
Hic2  CAGAGGCAAGCTATTAGTGA  
Hid1  TGATGACCGATACAACCTGT  
Serotype d characterization 150 
Hid2  TCCACTCTTCAAACCATTCT  
Hie1  GGTAACGAATGTAGTGGTAG 
Serotype e characterization 1350 
Hie2  GCTTTACTGTATAAGTCTAG  
Hif1 GCTACTATCAAGTCCAAATC 
Serotype f characterization 450 
Hif2  CGCAATTATGGAAGAAAGCT  
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Appendix 5.4. 
 
Table 5.4 | Primers used for MLST.23  
Primer name Sequence (5'- 3') Gene Expected amplified product (bp) 
adK-M13F TGTAAAACGACGGCCAGTGGTGCACCGGGTGCAGGTAA 
adK 477 
adK-M13R CAGGAAACAGCTATGACCCCTAAGATTTTATCTAACTC 
atpG-M13F TGTAAAACGACGGCCAGTATGGCAGGTGCAAAAGAGAT 
atpG 447 
atpG-M13R CAGGAAACAGCTATGACCTTGTACAACAGGCTTTTGCG 
frdB-M13F TGTAAAACGACGGCCAGTCTTATCGTTGGTCTTGCCGT 
frdB 489 
frdB-M13R CAGGAAACAGCTATGACCTTGGCACTTTCCACTTTTCC 
fucK-M13F TGTAAAACGACGGCCAGTACCACTTTCGGCGTGGATGG 
fucK 345 
fucK-M13R CAGGAAACAGCTATGACCAAGATTTCCCAGGTGCCAGA 
mdh-M13F TGTAAAACGACGGCCAGTTCATTGTATGATATTGCCCC 
mdh 405 
mdh-M13R CAGGAAACAGCTATGACCACTTCTGTACCTGCATTTTG 
pgi-M13F TGTAAAACGACGGCCAGTGGTGAAAAAATCAATCGTAC 
pgi 468 
pgi-M13R CAGGAAACAGCTATGACCATTGAAAGACCAATAGCTGA 
recA-M13F TGTAAAACGACGGCCAGTATGGCAACTCAAGAAGAAAA 
recA 426 
recA-M13R CAGGAAACAGCTATGACCTTACCAAACATCACGCCTAT 
M13F and M13R sequences are highlighted in grey. M13F primer was used for sequencing 
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Appendix 5.5. 
 
Table 5.5 | Primers used for each virulence gene.78,82,89 
Primer name Sequence (5'- 3') Gene Expected amplified product (bp) 
pilA1 ATGAAACTAACAACACAGCAAACC  
pilA  416 
pilA2 AAATAAAGAGGCATCCGTTCC 
ompP51  GCATTAGTAGTTGCTGGC 
ompP5  1040 
ompP52 TGCGATTTCTACACGACG  
hmw1A1 GAAACGCRRRTCCTTGAG 
hmw1A  149 
hmw1A2 GACTTGATGGTYYYYTGGTTGTAAA 
hmw2A1 CGAAACGCGTCCTTGAGAA  
hmw2A  200 
hmw2A2 TGCGCCATTACCACTTGAGAA 
hifA1 TGCTGTTTATTAAGGCTTTAG 
hifA  800 
hifA2 TTGTAGGGTGGGCGTAAGCC 
hia1 CAAAATTTTTAACGTTATTTGGAAT 
hia  3259 
hia2 AACGCCTGTTTTACCTTGACTAT 
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Appendix 5.6. 
 
 
Figure 5.1 | Antibiotic susceptibility panel worksheet. 
